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ABSTRACT 
Background: It has long been known that severe health anxiety is a common psychiatric 
condition associated with significant distress, functional impairment, and societal costs. 
Nevertheless, challenges remain with regard to the diagnosis and treatment of this disorder. 
As to diagnostic assessment, a recent shift in diagnostic taxonomy for individuals with severe 
health anxiety has led to a need for reliable instruments to aid clinicians and researchers in 
assessing the new diagnoses somatic symptom disorder (SSD) and illness anxiety disorder 
(IAD). As to treatment, individual face-to-face cognitive behaviour therapy (FTF-CBT) is the 
most researched and widely recommended treatment for severe health anxiety, but the 
availability of FTF-CBT is poor. Therapist-guided internet cognitive behaviour therapy 
(G-ICBT) may improve the scalability of evidence-based treatment, but it is unclear if this 
treatment could be efficacious and cost-effective also if delivered without a therapist or as 
book-form bibliotherapy. It is also unclear if the effect of G-ICBT is non-inferior to that of 
FTF-CBT. 
Aims: To develop, and evaluate the inter-rater reliability of, a structured diagnostic interview 
for the assessment of SSD and IAD (Study I). Also, to evaluate the efficacy of three forms of 
minimal-contact cognitive behaviour therapy for severe health anxiety (Study II) and to 
investigate their long-term efficacy and cost-effectiveness (Study III). Last, to determine if G-
ICBT is non-inferior to FTF-CBT in the treatment of severe health anxiety (Study IV). 
Methods: The inter-rater reliability of a new structured diagnostic interview for SSD and 
IAD was estimated based on concordance between the ratings of an interviewer and an 
independent clinician who listened to recorded interviews (Study I). The effects of different 
forms of minimal-contact cognitive behaviour therapy for severe health anxiety were also 
studied in two randomised controlled trials (RCTs). The first RCT (N=132) compared G-
ICBT, unguided internet cognitive behaviour therapy (U-ICBT), and cognitive behavioural 
bibliotherapy (BIB-CBT) to a waiting-list control (WLC) condition. Primary outcome was 
short-term change in health anxiety, as measured with the 64-item Health Anxiety Inventory 
(Study II). Among the secondary outcomes of this trial were long-term symptom levels up to 
1 year after treatment, and cost-effectiveness as based on the incremental cost-effectiveness 
ratio (ICER) vs. the WLC (Study III). The second RCT (N=204) compared G-ICBT to FTF-
CBT based on a non-inferiority criterion of 2.25 points on the 18-item Short Health Anxiety 
Inventory (d=0.3), as assessed over the 12-week treatment period (Study IV). 
Results: The inter-rater reliability of diagnostic decisions regarding SSD and IAD based on 
the new structured instrument – the Health Preoccupation Diagnostic Interview (HPDI) – was 
moderate (κ=.59) for clinical trial applicants, perfect (κ not applicable) for healthy controls, 
and almost perfect (κ=.85) for the pooled sample (Study I). G-ICBT, U-ICBT, and BIB-CBT 
all produced large waiting-list controlled reductions (d=0.80–1.27) in health anxiety (Study 
II). These effects were then sustained one year after treatment, and cost-effectiveness was 
high (waiting-list controlled ICERs=£ -134–416) for all three treatment formats (Study III). 
In the comparison of G-ICBT to FTF-CBT, the upper limit of the one-sided 95% confidence 
interval for the difference in change over the 12-week treatment period was 1.98 based on 
intention-to-treat data, and 2.17 based on per-protocol data. Both estimates were below the 
non-inferiority margin of 2.25 points, indicating that G-ICBT is not inferior to FTF-CBT in 
the treatment of severe health anxiety (Study IV).  
Conclusions: As hypothesised, the inter-rater reliability of SSD and IAD can be satisfactory 
if diagnoses are based on the HPDI, though the psychometric properties of this instrument 
need be studied further (Study I). G-ICBT, U-ICBT, and BIB-CBT are efficacious and cost-
effective treatments for severe health anxiety, with the potential to greatly increase treatment 
availability, not least in the primary and medical care context (Studies II and III). Because G-
ICBT is not inferior to FTF-CBT (Study IV), G-ICBT may be regarded as a first-line 
treatment for severe health anxiety, which calls for further implementation of this treatment 
format in routine care. 
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1 INTRODUCTION 
 
B. Death series C. Illness series 
 1) Being at a burial. 
2) Being at a house mourning. 
3) The word death. 
[…] 
 1) Hearing that an aquiantance has cancer. 
2) The word cancer. 
 […] 
 
From: Wolpe J. The systematic desensitization treatment of neuroses. J Nerv Ment Dis 1961; 132: 189-203. 
Reproduced with permission. 
Around 1960, Joseph Wolpe (1915–1997) laid out the basics of a therapeutic practice which 
would eventually evolve into exposure-based therapies as we know them today 1, 2. First in a 
case series, Mrs. A was described as suffering from a phobia “concerning illness and death” 
which “had its origin during childhood”. After approximately twelve sessions per hierarchy 
(“death” and “illness”, see above), Mrs. A was reported to have overcome this fear altogether. 
At the time, severe health anxiety was regarded to “respond rather badly” to psychotherapy 3, 
and a widespread idea was that a pathological fear of severe disease is always secondary to 
another psychiatric condition 4. In contrast, in the opinion of Wolpe, there was no doubt that 
the excessive fear described by Mrs. A was a problem in its own right, and that it was to be 
approached in more or less the same way as other syndromes that we now refer to as anxiety- 
or obsessive-compulsive spectrum disorders. 
Today, we know that severe health anxiety is a common problem with negative consequences 
for both the individual and society at large. A large number of clinical trials have also 
corroborated that cognitive behaviour therapy, which typically has much in common with the 
practices of Wolpe, is a highly efficacious treatment for severe health anxiety 5, 6. However, 
the availability of this type of treatment is still poor, and a major challenge of evidence-based 
mental health is to develop new strategies to reach and help as many patients as possible 7.  
The present thesis describes the development of new and efficacious methods of delivering 
exposure-based cognitive behaviour therapy for severe health anxiety. My hope is that the 
work here presented will contribute to reduced suffering and increased quality of life for the 
many suffering from this understudied condition. 
Stockholm, September 2018 
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1.1 SEVERE HEALTH ANXIETY 
1.1.1 A tentative definition 
Severe health anxiety, approximately the same thing as hypochondriasis a, is a psychiatric 
condition characterised by a persistent and excessive fear of, or preoccupation with, having or 
acquiring a serious health condition, such as terminal cancer or a progressive neurological 
disorder. This fear or preoccupation leads to clinically significant distress or functional 
impairment 8, and is typically accompanied by a preoccupation with bodily symptoms 9 and a 
strong fear of death 10. The conviction of being ill can be strong, but not delusional. A brief 
clinical vignette is presented below: 
 
 
 
a. The terms are often (but not always) used interchangeably, and their exact meanings vary over contexts. 
Whereas “hypochondriasis” is the traditional term, “health anxiety” and “severe health anxiety” are newer 
terms preferred by many researchers and clinicians to (1) reduce stigma 11, (2) emphasize similarities with 
other psychiatric conditions such as social anxiety disorder and general anxiety disorder 12 13, and (3) signal 
that worry about health is a dimensional phenomenon (i.e., it varies by degree) 14, 15. “Hypochondriasis” can 
refer either to a specific psychiatric diagnosis such as the hypochondriasis diagnosis of the DSM-IV, ICD-10, 
or ICD-11 (which all differ in terms of diagnostic criteria), or (more loosely) to a clinically significant form 
of worry about health, as sketched here (1.1.1). See also: 1.1.2–1.1.5.  
Ever since the death of her mother, Judy has gradually become more aware of her body 
and day-to-day physical sensations. Almost every time she experiences aches and pains, a 
slight nausea, fatigue, or muscle twitching, Judy worries about having cancer, a serious 
motor neuron disease, or an undiscovered heart defect. In an attempt to cope with the risk 
of being ill, Judy spends most nights researching medical information, explanations for 
her symptoms, and shopping for dietary supplements on the internet. In order to rule out 
the possibility of having a severe disease, Judy thoroughly examines her body for lumps, 
dots, and rashes at least two times a day, and also visits her general practitioner several 
times per month. So far, Judy has always been reassured by her doctor that her symptoms 
are not a sign of serious disease. This usually gives Judy a strong sense of relief, but it is 
typically not long before she is struck by the thought that something might have been 
missed. At the very least, she begins to worry about some other disease within the next 
few days. The persistency of Judy’s health anxiety has not only caused her sleep 
problems, but also taken a toll on her social and family life. Judy regularly discusses the 
seriousness of her symptoms with her partner, who has become gradually more frustrated 
with the situation, especially as Judy has become more preoccupied also with the health 
of her children. The thought of being seriously ill – perhaps even dying – has made Judy 
lose interest in many everyday activities, and she rarely gets in touch with her friends. On 
several occasions, Judy has also found the thought of having cancer so unbearable that 
she called in sick from work. Judy feels as though her body has become her worst enemy, 
and that she is always prepared for the worst. She would do anything to be certain, once 
and for all, that her symptoms are not worth worrying about. 
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1.1.2 Categorical versus dimensional perspectives 
Severe health anxiety has a broad set of cognitive, behavioural, and emotional characteristics. 
For example, individuals with this condition are prone to react to disease-related stimuli 16, 
and are more likely than others to interpret bodily symptoms as indicative of disease 17. On 
average, individuals with severe health anxiety also utilise more health care than others 18.  
In the general population such characteristics are highly correlated, and it is thus possible to 
regard health anxiety as a continuous psychological trait, i.e., a relatively stable pattern of 
cognition and behaviour which ranges on a continuum 19. In the present thesis, I henceforth 
use “health anxiety” to refer to this continuous trait, and “severe health anxiety” to denote the 
psychiatric condition in which the level of health anxiety has reached clinical significance. 
Notably, however, there appears to exist no non-arbitrary threshold to separate severe health 
anxiety from milder, presumably benign, forms of health anxiety 20-22. 
Historically, the categorical view of severe health anxiety as distinct from milder forms of 
health worries has nonetheless been more common than the dimensional view, and there may 
be advantages of both perspectives. For example, whereas the dimensional perspective 
facilitates the measurement of change, the categorical perspective could be argued to 
facilitate health care decisions, and constitute the foundation of evidence-based medicine 23. 
1.1.3 Diagnosis: the categorical perspective 
There is no expert consensus on the appropriate diagnostic criteria for severe health anxiety. 
Numerous taxonomies have been proposed; both historically 24-32 and in recent years 33-39. 
The precise boundaries between severe health anxiety and many other conditions such as 
functional somatic syndromes and obsessive-compulsive disorders are also disputed 40-42. 
This complicates comparison between studies, as well as research in the field in general. 
1.1.3.1 Somatic symptom disorder and illness anxiety disorder 
The most well-known, researched, and widely cited taxonomy for psychiatric syndromes is 
the Diagnostic and Statistical Manual of Mental Disorders (DSM), which is published by the 
American Psychiatric Association. The DSM is periodically revised as based on consensus 
(expert committees), and now exists in its fifth edition (DSM-5). According the DSM-5, most 
individuals with severe health anxiety meet criteria for somatic symptom disorder (SSD) or 
illness anxiety disorder (IAD) 38. An overview of key diagnostic criteria for SSD, IAD, and 
other common diagnoses in severe health anxiety is presented in Table 1. Two noteworthy 
differences between SSD and IAD are the presence of clear somatic symptoms in SSD but 
not IAD, and the much broader psychological core criterion in SSD as compared with IAD. 
There are three diagnostic specifiers for SSD. First, SSD can be classified as mild, moderate, 
or severe, as based on the presence of somatic symptoms and also the presence of excessive 
thoughts, anxiety, and/or behaviours. Second, there is a pain specifier, which denotes if pain 
is the primary somatic symptom or not. Third, there is a persistency specifier, which denotes 
whether the patient suffers from severe symptoms, marked impairment, and if the duration is 
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more than six months. There are two IAD specifiers. Patients may be classified as displaying 
excessive health-care seeking (i.e., care-seeking type) or avoidance of health care (i.e., care-
avoidant type). 
Table 1. Four psychiatric diagnoses to consider in severe health anxiety. 
Taxonomy DSM-IV ICD-11 DSM-5 
Diagnosis Hypochondriasis Hypochondriasis SSD IAD 
Psychological 
core criterion 
A preoccupation 
with the fear or idea 
of having a serious 
disease 
A persistent 
preoccupation with 
or fear about having 
a serious disease  
Either (1) 
disproportionate 
and persistent 
thoughts about the 
seriousness of-, (2) 
a persistently high 
level of anxiety 
about-, or (3) 
excessive time and 
energy devoted to 
somatic symptoms 
or health 
A preoccupation 
with having or 
acquiring a severe 
illness, a high 
level of anxiety 
about health, and 
the individual is 
easily alarmed 
about his or her 
health status 
Somatic 
symptoms 
Yes, the fear or idea 
is based on the 
misinterpretation of 
bodily symptoms 
Yes, the fear or idea 
is associated with 
the misinterpretation 
of bodily symptoms 
Yes, but not mild 
somatic symptoms 
No or only mild 
somatic 
symptoms 
Somatic 
symptoms may 
be explained by 
a severe disease 
No, the 
preoccupation 
persists despite 
medical reassurance 
No, the 
preoccupation 
persists despite 
medical reassurance 
Yes, but the 
psychological 
reaction has to be 
excessive 
Yes, but the 
psychological 
reaction has to be 
excessive 
Excessive illness 
behaviour 
Common but not 
required 1 
Yes Common but not 
required 
Yes 
Minimum 
duration 
Six months No Typically six 
months 
Six months 
Abbreviations: DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; DSM-5, Diagnostic and 
Statistical Manual of Mental Disorders 5; IAD, illness anxiety disorder; ICD-11, International Statistical 
Classification of Diseases and Related Health Problems 11; SSD, somatic symptom disorder. 
1 The individual has consulted health care, but not necessarily to an excessive extent. 
1.1.3.2 On the abandonment of DSM-IV hypochondriasis 
As illustrated in Table 1, the prototypical diagnosis for severe health anxiety in the DSM-IV 
was hypochondriasis. The DSM-5 work group that oversaw removal of the hypochondriasis 
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diagnosis also revised the “somatoform disorders” chapter of the DSM-IV as a whole. Most 
of these diagnoses (i.e., including pain disorder, somatisation disorder, and undifferentiated 
somatoform disorder) were criticised for having overlapping and seemingly arbitrary criteria. 
They were also criticised for being difficult to use in clinical practice 43, one reason being the 
difficulty in declaring somatic symptoms “medically unexplained”, and another reason being 
that “hypochondriasis” had become a pejorative term. 
The solution was to merge most of the somatoform disorders into one, namely the SSD 
diagnosis. Instead of requiring the patient’s somatic symptoms to be medically unexplained, 
the idea was to base a diagnosis on the presence of an excessive psychological reaction to the 
present health state (i.e., disproportionate thoughts, emotions, and/or behaviours). The IAD 
diagnosis was then added for those with severe health anxiety who do not experience distinct 
somatic symptoms. The assumption of the American Psychiatric Association was that of 
those who met criteria for DSM-IV hypochondriasis, approximately 75% would meet criteria 
for SSD, and approximately 25% would instead meet criteria for IAD 38. 
1.1.3.3 Reception and empirical status of SSD and IAD 
The transition from DSM-IV hypochondriasis to DSM-5 SSD and IAD has resulted in both 
optimism 44, 45 and controversy 39, 41. On the one hand, the introduction of SSD resonated with 
previous suggestions to combine different somatoform or functional somatic disorders 46-49, 
and with observed overlaps in key clinical characteristics 50, 51. On the other hand, a common 
view among researchers has also been that it is not clear that it is meaningful to separate 
individuals with severe health anxiety based on the presence (or non-presence) of somatic 
symptoms 39, 52, 53. When I initiated my PhD project in 2013, little empirical work had been 
done to explore this and other aspects of these new disorders. Over and above the DSM-5 
field trials 54, all studies of SSD and IAD had been based on post hoc research criteria 53, 55-57, 
and there existed no structured interview to aid clinicians and researchers in assessing these 
diagnoses to study them further. 
1.1.4 Symptom scales: the dimensional perspective 
Dimensional assessment of health anxiety is typically, though not always 58-60, based on self-
rated questionnaires 61-70 or continuous visual analogue scales 71, 72. One of the first scales to 
gain recognition as a valid measure of health anxiety was the Whiteley Index (WI). The WI 
was developed in the 1960s and based on clinicians’ definitions of “hypochondriasis” 73, and 
is still used as a symptom measure and outcome in clinical research 74-77.  
In the early to mid-1980s came the Illness Attitude Scales (IAS) which instead was based on 
statements made by patients who displayed abnormal illness behaviour 78 or thought that they 
had an undiagnosed disease 79. As in the case of the WI, the IAS has been referred to as the 
“gold standard for dimensional evaluation of hypochondriacal symptoms” 80 and used as 
outcome in several clinical trials 81-83. 
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Two decades later, the Health Anxiety Inventory was developed in an attempt to capture the 
cognitive, emotional, and behavioural characteristics of DSM-IV hypochondriasis 14. In the 
development of this scale, particular attention was also devoted to differentiating between 
individuals with high levels of health anxiety and those with actual somatic disease but not 
severe health anxiety. The Health Anxiety Inventory exists in one original 64-item version 
(HAI), and two shortened 18-item and 14-item versions (SHAI) 84. The HAI and SHAI have 
both gained recognition as psychometrically sound 14, 84, 85, and like the WI and IAS, the HAI 
and SHAI have also been used as primary outcome in clinical trials 86-88. 
1.1.4.1 Facets of the health anxiety construct 
A research topic that has received much attention is the dimensionality of health anxiety, i.e., 
whether there exist meaningful and relatively distinct components into which the health 
anxiety construct can be segmented. A commonly cited early principal component analysis 
indicated that the WI can be divided into (I) bodily preoccupation, (II) disease phobia, and 
(III) disease conviction 73. A commonly cited finding is that the IAS can be regarded as 
measuring (I) the cognitive and emotional characteristics of health anxiety and (II) illness 
behaviour 80. It is also common to refer to the IAS subscales introduced by the original 
author, which are: (I) worry about illness, (II) concerns about pain, (III) health habits, (IV) 
hypochondriacal beliefs, (V) fear of death, (VI) disease phobia, (VII) bodily preoccupation, 
(VIII) treatment experience, and (IX) the effects of symptoms 79. As to the HAI and SHAI, 
factor analyses are indicative of two or three factors. These have typically been interpreted as 
(I) illness likelihood (i.e., the fear of, and conviction of having, a serious illness), (II) negative 
consequences (i.e., catastrophic beliefs about having a serious illness), and in the case of three 
factors: (III) body vigilance 14, 84. On the whole, facets of health anxiety have varied much 
between different scales and populations 80, 85, 89. This being said, my impression is that (a) 
the fear or conviction of being ill and (b) bodily preoccupation or vigilance both appear to 
have explained a significant amount of variance, and emerged as distinct though correlated 
factors, in many studies. 
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1.1.5 Prevalence, demographics, and natural course 
Severe health anxiety is highly prevalent, though it is difficult to say precisely how prevalent. 
Typically, severe health anxiety has not been included in large-scale epidemiological surveys 
90, and estimates are difficult to contextualise due to differences in operationalisation and 
methodology 91. Factors likely to influence estimates include, but are not limited to: 
 Classification being based on either a self-rated questionnaire or clinical assessment 
 The precise choice of questionnaire, cut-off score, and/or diagnosis (see 1.1.3, 1.1.4) 
 The extent to which differential diagnoses are surveyed 
 If differential diagnoses are surveyed, the precise interpretation of the relationship 
between severe health anxiety and common differential diagnoses 
 Whether medical reassurance from a qualified health care professional is seen as a 
prerequisite for severe health anxiety, whether a medical examination is routinely 
conducted within the study itself, and if so the extent of this examination 
General population prevalence figures based on questionnaire cut-offs have been presented in 
the range of 6.4 to 8.3% 92-94. With the added requirement that the fear has lasted for at least 
six months despite medical reassurance, the prevalence sinks to around 3.4% 8. If differential 
diagnoses are also ruled out, and there is a requirement of clinically significant distress or 
functional impairment, most prevalence figures are closer to 0.1–0.6% 95, 96. This most 
restrictive operationalisation corresponds to the hypochondriasis diagnosis of the third and 
fourth versions of the DSM, on which most research on severe health anxiety has been based. 
Prevalence figures are notably higher among patients in medical care, where British estimates 
based on questionnaire cut-offs are in the range of 17.5–24.7% 97. 
It is commonly speculated that the prevalence of severe health anxiety is on the increase due 
to the emergence of the internet as a source of health-related information 98. Although this has 
face validity insofar as health-related information seeking has been shown to increase health 
anxiety 99, and online searches are no exception 100, there is no reliable way to determine if 
the prevalence of severe health anxiety is higher today than it was twenty or fifty years or 
ago. It may also be noted that there is a history of similar speculations regarding the impact of 
societal changes on health anxiety. In the 1960s, a presumed increase in the prevalence of 
severe health anxiety was attributed to “a spreading perversion of individualism” 101, in the 
1940s an increase was attributed to “the press and other agencies” 102, and in the 1930s: ”a 
decay of belief in a Divine providence” 103. 
Severe health anxiety is probably evenly distributed over genders and ages, and can debut at 
any age 8, 91, 104. For example, based on data from a recent clinical trial, I found that patients 
reported experiencing their first episode of severe health anxiety between 5 and 67 years of 
age, and that their present episode had lasted for 0.5 to 49 years. The finding that high levels 
of health anxiety can be seen also in children and adolescents has been replicated in several 
samples 61, 105-108. 
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As to natural course, the longest longitudinal study of severe health anxiety that I am aware 
of was 4–5 years, after which (54/85) 64% of medical outpatients diagnosed with DSM-III-R 
hypochondriasis still met criteria for this diagnosis. Studies by other research groups have 
been based on follow-up periods around 1 year, and presented figures of 16%, 48%, and 49% 
109. It is thus probably the case that approximately half of cases diagnosed with severe health 
anxiety are to be regarded as “chronic”, in the sense that spontaneous remissions is not to be 
expected within the next few years. 
1.1.6 Comorbidity, quality of life, and functional impairment 
On average, individuals with severe health anxiety report lowered quality of life 93, 110, and 
psychiatric comorbidity rates are high. For example, one study based on sampling from the 
general population of Australia compared individuals with severe health anxiety to those 
without severe health anxiety and found an odds ratio of 8.2 (95% CI, 4.2–16.0) for major 
depressive disorder, 10.6 (95% CI, 5.3–21.5) for panic disorder, and 9.3 (95% CI, 4.5–19.2) 
for generalised anxiety disorder 8; similar to the comorbidity of other anxiety disorders 111. 
Severe health anxiety is associated with functional impairment, not least in terms of cognitive 
and social capacities, as well as reduced capacity for emotion regulation 8, 18, 110, 112, 113. A high 
level of health anxiety is associated with low self-rated health 114, which in turn is a strong 
predictor of mortality even if health state and impairment is controlled for 115. A higher level 
of health anxiety is also predictive of a higher probability of ischaemic heart disease, 
regardless of whether common cardiovascular risk factors such as heritability and lifestyle 
factors are taken into account 116. 
1.1.7 Socioeconomic implications 
As a consequence of functional impairment, heightened health care utilisation 94, 95, 117, 118, 
and sick leave 8, 112, severe health anxiety is associated with considerable societal costs. This 
has been seen also in the Scandinavian context, where a Norwegian study has indicated that 
severe health anxiety is a strong predictor (crude OR=5.34 [95% CI, 3.69–7.75]) of disability 
pension award during 1–7 years of follow-up, and that the predictive power of health anxiety 
remains after adjustment for variables such as gender, income, general anxiety, and somatic 
conditions 119. There are also tentative results from Denmark indicative of an increase in 
sickness-related benefits 120 and health care costs 18 in individuals with severe health anxiety. 
The effects of such costs are underscored by the high prevalence of severe health anxiety in 
early years, in combination with the high probability of a chronic course (see 1.1.5). 
1.1.8 Neurobiology 
Although the specific neurobiology of health anxiety has rarely been studied, it is reasonable 
to assume that functional and structural neurobiological correlates of severe health anxiety 
largely coincide with those of fear learning and anxiety disorders 121-123, as well as correlates 
of functional somatic conditions and interoceptive awareness 124, 125. In other words, it is 
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reasonable to expect heightened health anxiety to be associated with deviations in activity of 
areas such as the amygdala, hippocampus, insula, anterior cingulate-, and prefrontal cortex. 
However, results have not been fully in line with this hypothesis. A recent study indicated 
that in response to health-related threat, high health anxiety was not associated with increased 
activation of the amygdala or anterior cingulate cortex 126. More in line with expectations, an 
earlier study showed that when exposed to words shown to elicit arousal in panic disorder 
(e.g., “heart attack”), individuals with panic disorder and individuals with severe health 
anxiety showed equally slowed reaction times and also similar deviations in brain activity 
(e.g., increased activation of prefrontal areas, thalamus, and the middle temporal cortex) as 
compared to healthy controls 127.  
As to structural correlates, one research group has presented preliminary evidence that health 
anxiety is associated with small left and right orbitofrontal cortex, large left but not right 
thalamus, small pituitary gland, but no deviations in caudate nucleus or anterior cingulate 
cortex volumes 128, 129. Studies cited under this segment have however been small, none of the 
findings have been replicated, and it is also unclear in which way functional and structural 
brain correlates are causally related to the aetiology or development of severe health anxiety. 
1.1.9 Aetiology and maintenance 
Health anxiety is modestly heritable with additive genetic factors explaining 10–37%, and 
non-shared environmental factors accounting for up to 63–90%, of the variance in facets of 
the construct 130. In contrast, the contribution of shared environmental factors appears to be 
approximately zero. This is comparable to the core symptoms of other anxiety disorders such 
as panic disorder and generalised anxiety disorder 131. 
Anecdotal evidence is sometimes cited to support the idea of a link between health anxiety 
and specific traumatic experiences, but most studies of specific environmental causes of 
severe health anxiety suffer from substantial methodological shortcomings 132-134. In most 
cases, designs have been cross-sectional and based on retrospective reporting vulnerable to 
reporting bias. Studies have generally not taken genetic variation into account, and risk 
factors have also not been shown to be specific for severe health anxiety (as opposed to other 
anxiety disorders). Given these many shortcomings, it is only natural that findings with 
regard to specific environmental risk factors for the development of severe health anxiety 
have typically not withstood replication 135, 136. 
This being said, authors of a recent systematic review of childhood and family factors in the 
development of severe health anxiety argued for a possible association with experiences of 
illness during childhood, including the experience of illness or death of a parent 137. For 
example, a recent study revealed that young adults (18–25 years old) with ill parents reported 
a higher mean level of health anxiety than young adults whose parents were not ill (d=0.21) 
138. There is a need for further research into such putative environmental risk factors for 
severe health anxiety. 
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1.1.9.1 A cognitive-behavioural model 
In the cognitive-behavioural field, the norm is to conceptualise severe health anxiety as an 
anxiety disorder, comparable to conditions such as panic disorder and generalised anxiety 
disorder 12. As in the case of all anxiety disorders, more is known about what maintains the 
condition than about what it is that causes it. Though it is common to refer to “the cognitive-
behavioural model” of severe health anxiety 139, 140, there have been several attempts at 
understanding health anxiety based on cognitive- or learning theory 13, 141-147, and also several 
influential models of similar constructs 148, 149. While most models of health anxiety and 
similar phenomena show considerable overlap, they also have their particularities, and some 
150 have little in common with the current mainstream view of severe health anxiety.  
A long-standing learning theory view of severe health anxiety is based on a two-factor model 
which incorporates respondent and operant learning 151. This model stipulates that a neutral 
stimulus (e.g., talk of cancer) is coupled with an unconditioned stimulus (e.g., the death of a 
loved one), which produces an unwanted emotional response (e.g., fear, anxiety) that is 
conditioned on the neutral (now conditioned) stimulus (factor 1). Negatively reinforced 
behaviours then become contingent on the conditioned stimulus, and maintain the 
conditioned response over time (factor 2). That is, in the example given, avoidance of talk of 
cancer may be reinforced by the short-term reduction in fear and anxiety. Avoidance of 
health-related stimuli (negatively reinforced in the short term or not 152) maintains the fear 
over time, by preventing new learning to change how the individual reacts to similar stimuli 
in the future. More could be said with regard to the controversy over the role of language and 
previous experience in relation to learning 153, the fact that the two-factor model leaves no 
apparent room for biology to explain why certain fears develop more easily than others 154, 
and why particular individuals appear to be more prone to fear learning than others. However, 
an exhaustive discussion of such matters lies beyond the scope of this thesis. 
Since the 1980s, it has become common to analyse health anxiety based on cognitive theory, 
which emphasises the role of information processing and beliefs in relation to perception and 
emotion 155. More specifically, cognitive theorists have commonly argued that the activation 
of dysfunctional assumptions such as “my body is weak and susceptible to illness” is likely to 
result in an increased focus on bodily processes and a bias toward the interpretation of bodily 
symptoms as indicative of disease 147. There has been speculation that in many cases, 
dysfunctional assumptions may result from early life experiences, such as being frequently 
encouraged to seek health care 147. Though health anxiety has been demonstrated to correlate 
with this type of dysfunctional assumptions 156, 157, no longitudinal study has, to my 
knowledge, shown that these typically precede other dimensions of severe health anxiety. 
Figure 1 illustrates a typical cognitive-behavioural model of how severe health anxiety is 
maintained over time. The model stipulates that an episode of health anxiety is initiated by 
one or several stimuli (A); either internal (e.g., headache) or external (e.g., a health-related 
text). This trigger is perceived in such a way that it gives rise to anxiety or fear about health 
(B); an emotional response that involves physiological changes such as increased heart-rate 
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and increased muscle tonus. Attention is increasingly devoted to health-related threats, such 
as those present in the own body (C). This leads to more stimuli (e.g., physical sensations) 
being viewed as threats, and threats being experienced as more intense (D). This, in turn, 
gives rise to behavioural responses (E), which persist because they reduce anxiety and/or fear 
in the short term, but also contribute to maintaining high levels of health anxiety over time. 
 
 
Fig. 1. Cognitive-behavioural model of severe health anxiety. Based loosely on the model of Hedman, Linde, 
Leiler, Andersson, Axelsson, and Ljótsson 158, in turn based on the work of Furer, Walker, and Stein 144. 
 
In accordance with the model (Figure 1), there is experimental evidence to support the claim 
that individuals with high levels of health anxiety are more prone than others to view health- 
and illness-related stimuli as threats to their own personal health 17, 159 (A–B), and to direct 
their attention to such stimuli 16, 160-162 (C). Individuals with high levels of health anxiety also 
tend to have a biased perception of health-related cues, such as their own heart rhythm 163, 164; 
a finding which ties in with a large empirical literature on the influence of expectancy over 
perception 165, 166, including interoceptive awareness 167. A simple verbal instruction to attend 
to one’s body is enough to induce a significant increase in the number of somatic sensations 
experienced, and such effects are most pronounced in individuals with high levels of health 
anxiety 168 (D). Studies support the view that health anxiety behaviours can lead to short-term 
reductions in health anxiety 169, 170, and also that, over slightly longer time periods, an 
increase in health anxiety behaviours can lead to an increase in health anxiety 99, and that a 
reduction in health anxiety behaviours leads to a gradual decrease in health anxiety 72, 81, 170. 
(E). In conclusion, there is firm evidence that cognitive and attentional distortions are implied 
in severe health anxiety, and that health anxiety behaviours maintain the condition over time. 
Trigger 
Interpretation 
Anxiety / fear 
Attention to threat  
(e.g., body sensations) 
Intensified triggers 
(e.g., bodily sensations) 
Checking, reassurance seeking, 
preventive behaviours, avoidance 
Temporary reduction 
of anxiety / fear 
A 
B 
C 
D 
E 
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However, why health anxiety behaviours have these effects is not entirely clear. From the 
standpoint of learning theory, negatively reinforced illness behaviours (e.g. frequent symptom 
checks) are thought to maintain severe health anxiety because they prevent habituation to 
aversive stimuli (e.g. unattended and unfamiliar physical sensations). Alternatively, illness 
behaviours may primarily serve to prevent new learning of other, more adaptive, responses to 
the same stimuli 171. Warwick 13 was early to propose three cognitively-oriented hypotheses 
regarding the mechanisms behind the detrimental effect of excessive illness behaviours in 
severe health anxiety. First, many illness behaviours (e.g. regular pulse checks) may prevent 
individuals with severe health anxiety from learning that their feared outcomes (e.g. to suffer 
a heart attack) would not come true even if they acted differently (e.g. stopped monitoring 
their pulse). Second, some illness behaviours paradoxically bring about new triggers for 
health anxiety. For example, repeated pinching and scratching aimed at examining rashes 
might irritate the skin, and monotonous movements aimed at assessing hand mobility and 
strength may induce fatigue and numbness. Third, illness behaviours may continuously serve 
to remind individuals with severe health anxiety of the very fear that they are trying to 
escape. For example, an individual that routinely examines his or her stool for blood 
indicative of colorectal cancer may be primed to think of this disease when confronted with 
ambiguous stimuli, and may also be more likely than others to notice minimal anomalies. 
1.1.10 Summary and current directions 
Severe health anxiety is characterised by a persistent and excessive fear of, or preoccupation 
with, having or acquiring a serious health condition, and may be regarded as an extreme form 
of health anxiety; a multifaceted psychological trait which incorporates cognitive, emotional, 
and behavioural dimensions. According to the DSM-5, most individuals with severe health 
anxiety meet criteria for somatic symptom disorder (SSD) or illness anxiety disorder (IAD). 
Prior to the present project, little research had been devoted to SSD and IAD, and there was a 
need for a structured diagnostic instrument to aid clinicians and researchers studying these 
disorders further. 
The prevalence of severe health anxiety in the general population is approximately 0.5–5%, 
but much higher in the primary care and medical clinic context. The disorder not only leads to 
significant suffering, impairment, and lowered quality of life for the individual, but is also 
responsible for sizable societal costs. Although little is known about the aetiology of severe 
health anxiety, there is strong evidence that the disorder is at least to some degree maintained 
through negatively reinforced illness behaviours. 
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1.2 COGNITIVE BEHAVIOUR THERAPY (CBT) FOR SEVERE HEALTH 
ANXIETY 
1.2.1 A typical protocol 
The treatment that enjoys the largest evidence base in the treatment of severe health anxiety is 
cognitive behaviour therapy (CBT); an umbrella term to denote a heterogeneous family of 
psychological treatments primarily based on cognitive and/or learning theory 5, 13, 172, 173. CBT 
for severe health anxiety is typically based on the type of model presented under 1.1.9.1, and 
typically involves the following components: 
 Self-monitoring 
 Psychoeducation 
 Exposure and response prevention and/or cognitive restructuring techniques 
Self-monitoring is a practice where the patient is instructed to register, or keep some sort of 
journal, of the situations believed relevant for the problem at hand. This is usually intended 
both to increase the patient’s understanding for his or her own difficulties, and as a means to 
collect information necessary for working with exposure and/or cognitive techniques (below). 
Psychoeducation is the provision of information about psychological processes believed to be 
of relevance for the patient, such as how learning-, attentional-, and physiological processes 
contribute to the emergence and maintenance of health anxiety. This too can be seen either as 
an intervention in its own right, or as a prerequisite for working with other interventions. 
In exposure and response prevention (ERP), patients systematically approach aversive stimuli 
(i.e., exposure) while refraining from attempts at short-term anxiety reduction (i.e., response 
prevention) 174. An example would be reading feared texts about a particular disease and 
thereby inducing health anxiety, without taking steps to reduce this emotional response, e.g., 
by discussing symptoms with others or visiting a health-care professional. Exposure exercises 
may be either interoceptive, in vivo, or imaginal 172. Interoceptive exposure is exposure to 
physical sensations, typically produced through standardised exercises. Patients may for 
example be encouraged to hyperventilate so as to induce acute respiratory alkalosis and 
symptoms such as nausea and palpitations. In vivo exposure is exposure to “real life” outer 
stimuli such as a hospital or a newspaper article. Finally, imaginal exposure is exposure to 
anxiety-inducing thoughts and mental images, such as those of how it would be to develop 
motor neurone disease. 
Cognitive restructuring techniques have as their common aim to change characteristics of the 
patient’s cognition, and specifically those aspects believed to maintain severe health anxiety. 
In practice, what is referred to is usually interventions based on a particular strain of theory 
about cognition, and in particular abnormal cognition in psychopathology 147, 155 (see also 
1.1.9.1). One common way of accomplishing cognitive restructuring is through so called 
behavioural experiments 175, where exposure to triggers for health anxiety is used as a means 
of subjecting the patient’s health-related assumptions and predictions about the world to 
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empirical investigation. In concrete terms, a patient who avoids heavy training due to a fear 
of myocardial infarction may for example be asked to engage in training as a behavioural 
experiment, with the aim of testing the hypothesis that this will lead to a heart attack. 
There is a discussion among researchers and clinicians about the relationship between 
behavioural experiments and ERP 175-177. The terms are reflective of theoretical emphasis; the 
former having grown out of cognitive-, and the latter of behaviour therapy 175, 178. The aim of 
ERP has traditionally been seen as achieving extinction (unlearning) of responses to triggers 
for anxiety, and most treatments incorporating ERP have instructed patients to complete a 
large number of exposure exercises with the aim of achieving habituation; a reduction of the 
emotional response, thought to be indicative of new learning 171, 179, 180. In contrast, treatments 
based on behavioural experiments have traditionally emphasised the importance of changing 
dysfunctional thoughts and assumptions through the process of collaborative empiricism 181, 
i.e., that the patient and therapist engage in a joint investigation into the empirical status of 
the patients’ thoughts and beliefs, and that behavioural experiments are designed so that they 
target specific thoughts intended for evaluation 175. 
Contrary to long-held dogma, there is preliminary evidence that habituation (at least the 
degree to which habituation is achieved within each exposure session) is not predictive of 
outcome in exposure therapy 171, and that rather than being a corrective process by which a 
fear memory is gradually diminished or replaced, exposure works by producing non-fear 
associations which coexist and “compete” with the fear memory 182. There are experimental 
studies which suggest that the efficacy of exposure therapy may be determined by other 
factors than habituation, including the variability of exposure, the degree to which the 
outcome of an exposure session is unexpected, and the degree to which a broadening of the 
patient’s behaviour repertoire is achieved 171, 183. This theoretical framework may be relevant 
for both exposure and behavioural experiments, and has further blurred the line between the 
two, which are also likely to be approximately equally efficacious in the treatment of severe 
health anxiety 184. 
1.2.1.1 The protocol here investigated 
In the clinical trials detailed in this thesis (see 3.2–3.5), CBT for severe health anxiety was 
based on a mainstream CBT model of severe health anxiety (see 1.1.7.1). The initial phase of 
treatment focused on self-monitoring and psychoeducation, and subsequent work focused on 
ERP. The rationale for ERP focused primarily on the importance of habituation, and was thus 
a relatively traditional exposure-based CBT with little reference to cognitive theory. Brief 
mindfulness exercises were also introduced as a method of inducing and enhancing exposure, 
e.g., by reducing covert (i.e., unobservable) negatively reinforced illness behaviours, such as 
symptom-checking and worrying about heath. For an overview of the treatment, see Table 2.  
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Table 2. Schematic overview of the treatment protocol investigated in this thesis. 
Module/ 
Session 
Main theme Main homework exercise 
1 Introduction to health anxiety and CBT Behaviour diary, mindfulness exercise 
2 A model of severe health anxiety Idiosyncratic model, mindfulness exercise 
3 Interoceptive exposure Interoceptive exposure, mindfulness exercise 
4 Response prevention Response prevention, mindfulness exercise 
5 Exposure in vivo Exposure and response prevention 
6 Imaginal exposure Exposure and response prevention 
7 Imaginal exposure, thoughts about death Exposure and response prevention 
8 Common obstacles to exposure Exposure and response prevention 
9–10 Exposure continued Exposure and response prevention 
11 
Summary of the treatment, relapse 
prevention 
Exposure and response prevention, summary  
12 Focus on the future 
Exposure and response prevention, relapse 
prevention, how to deal with health care 
Abbreviations: CBT, cognitive behaviour therapy. 
1.2.2 Less common protocols 
There exists a number of therapies which could be said to be based on cognitive- or learning 
theory, but which employ a combination of treatment components that is unconventional and 
relatively experimental in the treatment of severe health anxiety. Some of these less common 
protocols have nevertheless been included in influential reviews of CBT for severe health 
anxiety 185, 186, where, unfortunately, no distinction was made in relation to the most common 
type of protocol that is the main focus of this thesis (1.2.1). For sake of clarity, here follows a 
description of less common protocols that have been tried for severe health anxiety, and an 
attempt at briefly highlighting why these differ from the conventional form of CBT for severe 
health anxiety. 
Acceptance and commitment therapy is a treatment which does not employ ERP or cognitive 
strategies in the conventional sense. Unlike traditional CBT, the treatment is explicitly built 
around increasing psychological flexibility, which is the ability to “[get in contact with] the 
present moment fully as a conscious human being, and based on what the situation affords, 
[change] or [persist] in behaviour in the service of chosen values” 187. Acceptance and 
commitment therapy has been demonstrated to be efficacious for severe health anxiety in one 
pilot study and one RCT with a large waiting-list controlled effect 188, 189. A pilot study has 
also indicated that it is feasible to deliver acceptance and commitment therapy for severe 
health anxiety via the internet 190. 
Attention training therapy is concerned with the reduction of self-focused attention believed 
to elicit and exacerbate health anxiety 191. There is a connection to cognitive theory in that 
lowered attention to physical sensations is believed to lead to more accurate beliefs about 
symptoms 192, but attention training therapy does not involve any other varieties of cognitive 
restructuring or exposure. Attention training therapy has been demonstrated to be efficacious 
for severe health anxiety in one small case series study 192. A small RCT (N=36) also found 
no significant difference in the effect on health anxiety in comparing three weeks of attention 
training therapy to three weeks of response prevention (d=0.11) 72. 
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Behavioural stress management is based on the assumption that some react to stress with 
severe health anxiety, and the intervention aims to reduce this reactivity by relaxation 
training, problem solving, and health-promoting behaviours such as physical training and a 
dietary changes. Unlike conventional CBT for severe health anxiety, behavioural stress 
management does not involve ERP or cognitive restructuring. Behavioural stress 
management for severe health anxiety has been evaluated in two RCTs. Both RCTs were 
indicative of large within-group effects, and one trial reported a large waiting-list controlled 
effect on health anxiety 71, 193. When compared to conventional CBT, behavioural stress 
management has been shown to be inferior, but the difference has been small to moderate in 
size 71, 193, with no difference at long-term follow up 71. In one of the RCTs, behavioural 
stress management was delivered via the internet, which shows that this is a viable format 193. 
Explanatory therapy is a straightforward educational program which emphasises the role of 
perception and emotions in relationship to somatic symptoms. As in conventional CBT, a key 
aim is to make the patient aware of how selective attention to bodily processes is likely to 
increase health anxiety over time, and the provision of information is also intended to lead to 
extinction of “the emotional component” of severe health anxiety 194. However, unlike in the 
case of conventional CBT, explanatory therapy does not involve orthodox exposure or 
cognitive techniques. Instead, distraction from aversive stimuli is encouraged, and medical 
reassurance is seen as a component of the intervention 194. Explanatory therapy has been 
efficacious in one RCT with a large waiting-list controlled effect on health anxiety 195. 
Metacognitive therapy does not aim to challenge dysfunctional assumptions about health in 
the same way as conventional CBT. Instead, the treatment focuses on reducing worry and 
maladaptive coping by changing negative metacognitive beliefs (e.g., “It is impossible for me 
to stop worrying about my health if there is no medical explanation for my symptoms”), and 
by incorporating attention training techniques in the treatment. Metacognitive therapy has 
showed promise in a single case design study of four patients, which demonstrated large 
reductions in health anxiety that were sustained at six months follow-up 196. 
Mindfulness-based cognitive therapy combines some of the educational aspects of 
conventional CBT with a strong emphasis on mindfulness meditation. The treatment aims to 
develop a more accepting and less reactive stance towards thoughts and emotions, and also to 
prevent future relapse 146. There is also an emphasis on approaching aversive thoughts with 
curiosity and feelings of compassion 197, and to engage with the present moment in a way 
thought to be incompatible with anxiety 146. However, the treatment does not involve 
conventional ERP or cognitive techniques. Mindfulness-based cognitive therapy has been 
shown to produce a reduction in health anxiety in one small pilot study 198, and was superior 
to a treatment-as-usual condition in one RCT 199.  
Problem-solving therapy is, like conventional CBT, a practical and highly structured 
treatment, but the focus of the treatment is on acquiring problem solving as a coping skill, 
rather than working with exposure or cognitively-oriented strategies. A controlled trial 
(N=48) where the treatment allocation was a function of admission date did not show any 
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noteworthy difference in effect between six weeks of problem-solving therapy and six weeks 
of education in accordance with a conventional CBT model. There was a moderate to large 
reduction of health anxiety in both groups, and this was sustained up to six months after 
treatment 200. 
1.2.3 Treatment delivery formats 
There are many ways to deliver CBT. In the present thesis, minimal-contact CBT denotes 
those delivery formats which involve little or no contact with a therapist. Regardless of 
delivery format, CBT for severe health anxiety rests on the same theoretical foundation and 
behavioural strategies (see 1.1.9.1 and 1.2.1). 
1.2.3.1 Individual face-to-face CBT (FTF-CBT) 
Individual face-to-face CBT (FTF-CBT) is the most researched and widely recommended 
form of CBT for severe health anxiety, and anxiety disorders in general 201. In FTF-CBT, the 
patient has regular meetings with a therapist, and most of the communication is done face-to-
face. The treatment is approximately 5–15 weeks long, with weekly 30–60-minute sessions 5. 
Between these sessions, the patient engages in homework exercises and applies the treatment 
principles in everyday life. This work is typically guided by the use of worksheets, which are 
completed in pencil and paper format, and continuously reviewed at each treatment session. 
1.2.3.2 Minimal-contact CBT (G-ICBT, U-ICBT, and BIB-CBT) 
In conventional therapist-guided internet CBT (G-ICBT), the treatment content is conveyed 
in text form, via a secure online treatment platform where the patient is assigned a personal 
account (Figure 2). The text is usually approximately 100–150 A4 pages long, and segmented 
into 5–15 chapters, commonly referred to as modules, which include educational material and 
instructions for behaviour change. 
Throughout the treatment, the patient communicates with a therapist through asynchronous, 
email-like, text messages via the treatment platform. The therapist is the same over the entire 
treatment period, but the role of the therapist is somewhat different to that in FTF-CBT. In G-
ICBT, the focus is more on emotional and technical support, and less on psychoeducation 202. 
This is because the treatment content is highly structured, and most information necessary to 
induce behaviour change is already provided in the modules 203, 204. 
It is typically the case that the patient is expected to complete approximately one module per 
week, which is to say that the patient is expected to read the material, work with the intended 
homework exercises, and answer a series of written questions intended to stimulate reflection 
and feedback to the therapist. In other words, like FTF-CBT, G-ICBT is a practical treatment 
where the patient is expected to complete the equivalent tasks and behaviour changes, and the 
typical length of G-ICBT (ca 8–12 weeks) is also very similar to that of FTF-CBT.  
Access to new treatment modules is typically given sequentially by the therapist, at the pace 
at which modules are completed by the patient. As in FTF-CBT, several procedures of the 
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treatment are guided by the use of worksheets. These are presented on the treatment platform, 
completed and stored online, and can be accessed by both the patient and therapist (Figure 2). 
 
 
Psychoeducational material. 
 
Interactive worksheet. 
 
Written questions for reflection and feedback. 
 
Email-like communication with the therapist. 
Fig. 2. Online treatment platform in therapist-guided internet cognitive behaviour therapy (G-ICBT). 
 
A slightly different treatment format is unguided internet CBT (U-ICBT), which as the name 
suggests is the very same thing as G-ICBT but without a therapist. That is, as in the case of 
G-ICBT, the patient is expected to work with the treatment content which is presented in text 
form, divided into modules, on a web-based platform. As is the case with G-ICBT, the basic 
tenet of U-ICBT is also that the patient is to work with the very same types of exercises and 
behaviour changes as in FTF-CBT 205. 
In cognitive-behavioural bibliotherapy (BIB-CBT), CBT is administered via a structured self-
help text which is presented in book form rather than on an online platform 206, 207. Thus, the 
modules of G-ICBT and U-ICBT take the form of book chapters, and the aim is to convey the 
information necessary for the patient to work with the same exercises and strategies thought 
to produce therapeutic effects in FTF-CBT. BIB-CBT can imply various degrees of therapist 
support; anywhere from no support at all, to several face-to-face sessions with a therapist 208. 
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1.2.4 Systematic review of RCTs of CBT for severe health anxiety 
Techniques reminiscent of present-day CBT were used in the treatment of severe health 
anxiety at least as early as the 1960s 1. Yet it is only since the mid-1990s that the effects of 
CBT on this condition have been evaluated in RCTs; often regarded as a gold standard design 
of clinical trials to inform evidence-based practice, due to the control over confounding 
variables 23, 209. Here follows a systematic literature review of RCTs to compare CBT (see 
1.2.1 for details) to at least one other condition in the treatment of severe health anxiety. I 
searched PubMed and PsycINFO last on June 7th, 2018, and assessed all references from 
previous reviews 5, 173, 185, 186. 
Not counting the present project, the search identified 13 RCTs 71, 75-77, 81, 83, 86-88, 193, 210-212, 
which involved 20 comparisons of CBT and a control (total unique N=1491): 9 vs. a waiting-
list, 4 vs. another psychological intervention, 2 vs. treatment-as-usual, 2 vs. an antidepressant, 
2 vs. a pill placebo, and 1 vs. a psychological placebo. Meta-analyses are here based on 
random effects models fitted under restricted maximum likelihood, self-report symptom 
measures, and the Hedges’ g effect size, for which it is common to interpret absolute values 
of 0.20 as small, 0.50 as moderate, and 0.80 as large 213. Heterogeneity among studies is 
reported based on the Q- and I2-statistics, where the latter denotes the percentage of the 
variance between studies attributable to true differences between studies rather than random 
(sampling) error. A common way to interpret I2 is that 25%, 50%, and 75% stand for low, 
moderate, and high heterogeneity, respectively 214. The aggregate overall controlled effect 
size of all comparisons (Figure 3) was large (g=0.86 [95% CI, 0.61–1.11]), and as expected 
given the great variety in control groups, heterogeneity was large (Q19=83, P<.001; I
2=80%). 
Fig. 3. Meta-analysis of self-rated health anxiety in randomised controlled trials of cognitive behaviour therapy 
versus another condition in the treatment of severe health anxiety. Random-effects model fitted under restricted 
maximum likelihood, and with effects expressed as Hedges’ g. Abbreviations: CBT, cognitive behaviour 
therapy; FTF-CBT, individual face-to-face cognitive behaviour therapy; G-ICBT, therapist-guided internet 
cognitive behaviour therapy; Placebo psy, psychological placebo; TAU, treatment-as-usual; WLC, waiting-list. 
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1.2.4.1 Efficacy of individual face-to-face CBT (FTF-CBT) 
Ten of the 13 RCTs concerned FTF-CBT, and the mean number of sessions in these trials 
was 11.1 (SD=4.2). Based on 13 unique FTF-CBT groups, the aggregate within-group effect 
on health anxiety was large (g=1.64 [95% CI, 1.38–1.90]), with moderate heterogeneity 
(Q12=26, P<.011; I
2=59%). There was also a large pooled within-group effect on secondary 
symptoms of depression (g=0.91 [95% CI, 0.69–1.14]) and general anxiety (g=0.94 [95% CI, 
0.50–1.38]). 
Nine out of fifteen comparisons were against a waiting-list, and based on these the aggregate 
controlled effect of FTF-CBT was large (g=1.22 [95% CI, 0.99–1.44]). Heterogeneity was 
non-significant (Q8=6, P<.672; I
2=0%), and there was no indication of publication bias. In the 
largest RCT of FTF-CBT for health anxiety, 445 patients with DSM-IV hypochondriasis in 
British medical clinics were randomised to five to ten sessions of FTF-CBT or to a treatment-
as-usual condition. At the primary endpoint one year after inception there was a 2.98 point 
(95% CI, 1.09–4.23) advantage of FTF-CBT, equivalent to g=0.68, on the 14-item SHAI 86. 
Responder rates in FTF-CBT, defined as the proportion of patients who saw their symptoms 
decrease by a clinically significant degree, were reported based on three of the RCTs 76, 77, 215. 
The aggregate responder rate in FTF-CBT was 57% (95% CI, 44–70%), with one study 
reporting NNT=2.0 (95% CI, 1.5–3.1) versus a waiting-list over six weeks 76. Remission rates 
for FTF-CBT, defined as the proportion of patients who scored below a cut-off for severe 
health anxiety, have only been reported in two RCTs 86, 215, with an aggregate remission rate 
of 38% (95% CI, 11–65%). Clinically significant improvement after FTF-CBT, defined as a 
reliable reduction in symptoms combined with a score below a cut-off for severe health 
anxiety 216, was estimated to be 54% (95% CI, 42–66%) based on two RCTs 75, 83. 
As to controlled effects on secondary symptom domains, the aggregate waiting-list controlled 
effect on depression was moderate (g=0.61 [95% CI, 0.28–0.93]; 9 comparisons), and so was 
the effect on general anxiety (g=0.70 [95% CI, 0.41–0.99]; 7 comparisons). Based on the four 
RCTs which explored the long-term effects of FTF-CBT on health anxiety around 5–6 
months after treatment 71, 210, 211, 217, the within-group change in the FTF-CBT-group from 
post-treatment was approximately zero (g=0.01; [95% CI, -0.27–0.29]), and there was a small 
advantage over treatment-as-usual 86, 210, but no significant controlled effect against 
behavioural stress management 71 or pharmacotherapy 217. Three RCTs presented data from a 
12-month follow-up 71, 86, 211, and the aggregate within-group change from post-treatment was 
larger, in the direction of an increase in symptoms, but still not significant (g=0.24 [95% CI, -
0.01–0.49]). 
1.2.4.2 Efficacy of therapist-guided internet CBT (G-ICBT) 
Three out of the 20 comparisons concerned G-ICBT. Because these three RCTs had different 
control groups, their outcomes are here described separately. First, one RCT (N=81) 
compared 12 weeks of exposure-based G-ICBT (1.2.1.1) to an attention control condition 
where patients took part in an online forum. There were large controlled reductions in health 
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anxiety as measured with the HAI (g=1.60), and also in secondary symptoms of depression 
(g=1.19) and general anxiety (g=1.04) 88. The improvement of the G-ICBT group was 
sustained up to one year after treatment 218. 
A second RCT (N=158) compared the same exposure-based G-ICBT protocol to internet 
behavioural stress management, and found a small controlled effect of G-ICBT on health 
anxiety (g=0.26), but no difference in terms of secondary symptoms of depression (g=0.05), 
general anxiety (g=0.09), or functional impairment (g=0.00). The within-group effect of G-
ICBT was large, and the improvement of the G-ICBT group was sustained at follow-up, six 
months after treatment 193. 
A third RCT (N=102) by another research group was published in parallel with the present 
project, and compared 12 weeks of G-ICBT to a condition where patients were provided with 
fortnightly online educational content pertaining to anxiety, and offered contact with a 
clinician via e-mail or phone. At post-treatment, there was a large controlled effect of G-
ICBT on health anxiety (g=1.40), and moderate controlled effects on depression (g=0.44), 
general anxiety (g=0.78), and functional impairment (g=0.53). The proportion of missing data 
in this trial was relatively high, with (37/51) 73% in G-ICBT vs. (32/51) 63% in the control 
condition completing the post-treatment assessment, and (31/51) 61% of the G-ICBT group 
completing the three-month follow-up. Although this means that the effect sizes are likely to 
be distorted, the controlled effect on health anxiety was so large that the main conclusion that 
G-ICBT was more efficacious than the control group is likely to be valid 87. 
1.2.4.3 Risk of bias 
Based on the criteria of the Cochrane collaboration 219, the risk of bias pertaining to the health 
anxiety outcomes aggregated in this systematic review was relatively low (Figure 4). The 
largest threat in this respect was incomplete outcome data, and the employment of inadequate 
imputation techniques. I did not rate the criterion “blinding of outcome assessment” because 
all outcomes used for the systematic review were self-rated, and it is debatable if this should 
generate a rating of “high” or “low” risk of bias. 
 
Fig. 4. Ratings based on the Cochrane collaboration’s tool for assessing the risk of bias. 
0% 25% 50% 75% 100%
Selective reporting
Incomplete outcome data
Allocation concealment
Random sequence generation
Low risk of bias Unclear risk of bias High risk of bias
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1.2.5 Predictors of treatment effect 
A handful of studies have investigated predictors of treatment effect in CBT (in any format) 
for severe health anxiety 220-224. It should however be noted that very different sets of putative 
predictors have been investigated in different studies, that studies have been based on very 
different types of statistical models (and promising models have never been validated in new 
samples), that there have been clear limitations with regard to statistical power and restriction 
of range, and that studies have been based on stepwise regression procedures known to 
produce biased parameter estimates and be susceptible to multiple comparison, ordering, and 
overfitting effects 225, 226. The most stable finding has been that higher baseline health anxiety 
220, 222-224, 227 is predictive of larger treatment effect, perhaps reflective of regression towards 
the mean. Larger effects may also possibly be predicted by lower baseline depression 173, 224, 
stronger therapeutic alliance 220, 228, and higher treatment adherence 220, 224, but probably does 
not depend (at least to a noteworthy degree) on demographic characteristics such as gender, 
age, or socioeconomic status 220-224, 227, 228. 
1.2.6 Evidence for delivery formats 
1.2.6.1 Efficacy of individual face-to-face CBT (FTF-CBT) 
Based on the systematic review presented above, FTF-CBT for severe health anxiety has a 
large effect on health anxiety, large effects on secondary symptoms of depression and general 
anxiety, and improvements are maintained at least up to six months after treatment. This has 
been corroborated by non-controlled trials 6, including well-reported single-case designs 169, 
as well as at least one cluster-randomised trial 74. FTF-CBT has been shown to work in 
clinical practice 86, and it is efficacious also based on outcomes assessed by clinicians 81, 212. 
The waiting-list controlled effect of FTF-CBT on health anxiety is comparable to the effect 
on core symptoms of other anxiety disorders such as panic disorder, social anxiety disorder, 
and generalised anxiety disorder 229. In terms of response, remission, and clinically significant 
improvement, the effects of FTF-CBT are also similar to those seen in other anxiety 
disorders, where the typical finding is that approximately half of the sample meet such 
criteria at post-treatment 230. It is debatable if FTF-CBT for severe health anxiety meets the 
American Psychological Association criteria for an “empirically supported treatment” 231 
(i.e., the highest level of evidence), which requires superiority over a placebo or another 
active treatment in at least two independent trials by independent research groups. This is 
because one out of two RCTs where FTF-CBT has been demonstrated to be more efficacious 
than an active control was a cooperative project involving two research groups 71, 211. My 
conclusion is nevertheless that the evidence base for FTF-CBT in the treatment of severe 
health anxiety is strong. 
1.2.6.2 Efficacy of minimal-contact CBT (G-ICBT, U-ICBT, and BIB-CBT) 
Prior to the present project, no direct comparisons of FTF-CBT, G-ICBT, U-ICBT, or BIB-
CBT had been done in the treatment of severe health anxiety. Speculation into the relative 
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efficacy of these delivery formats therefore had to be based either on indirect comparison of 
effects in different studies, or on direct comparison of effects on other psychiatric conditions. 
The three RCTs surveyed under 1.2.4.2 suggest that the effects of G-ICBT on severe health 
anxiety can be similar to those of FTF-CBT. This is in line with the more than 100 RCTs of 
G-ICBT in the treatment of psychiatric and somatic conditions 232, where at least 38 RCTs 
have focused on the treatment of anxiety disorders 233. A recent meta-analysis based on direct 
comparisons of G-ICBT and FTF-CBT for psychiatric and somatic conditions demonstrated 
an aggregated controlled effect size that was close to zero (g=0.05 [95% CI, -0.09–0.20]) 234. 
In other words, it is probably the case that for most patients and most conditions, G-ICBT is 
as efficacious as FTF-CBT. It could however be that the difference in effect depends on the 
condition to be treated. Prior to this project, a direct comparison between G-ICBT and FTF-
CBT in the treatment of severe health anxiety had never been conducted. 
As to minimal-contact CBT without a therapist, two published clinical trials of BIB-CBT 
could be of interest, but could not be included in the systematic review (1.2.4). First, a small 
RCT (N=40) saw promising waiting-list controlled effects of four weeks of BIB-CBT, but 
was based on an unconventional operationalisation of severe health anxiety, and large group 
differences in symptom levels at baseline 235. Second, another waiting-list controlled trial 
(N=40) focused on patients who met criteria for DSM-IV hypochondriasis. This trial also 
showed promising results, but did not employ randomisation and also suffered from a high 
level of attrition 236. These methodological limitations make it difficult to draw conclusions 
about the efficacy of BIB-CBT for severe health anxiety. 
For most conditions, a typical finding has been that therapist-guided CBT (e.g., G-ICBT) is 
more efficacious than unguided CBT (e.g., U-ICBT and BIB-CBT). A meta-analysis of 2014 
identified eight direct comparisons of G-ICBT and U-ICBT for any psychiatric disorder 237, 
and found that G-ICBT (i.e., therapist support) was associated with a slightly larger effect on 
primary symptom measures (SMD=-0.27 [95% CI, -0.45–-0.10]), and also better odds for 
treatment completion (OR=2.76 [95% CI, 1.68–4.53]). Similarly, a review of internet CBT 
published in 2007 205 showed a strong positive correlation (ρ=0.75; P<0.01) between the time 
that therapists spent per patient and effect on the primary outcome. It is however difficult to 
interpret the latter finding because likely confounders such as treatment length and means of 
recruitment were not taken into consideration. It should also be noted that recent direct 
comparisons of G-ICBT and BIB-CBT 238-240 have shown surprisingly similar results of these 
treatment formats. 
1.2.7 Mediators of change 
Given that CBT has now been demonstrated to be efficacious for severe health anxiety, the 
focus of research has increasingly turned not only to the challenge of dissemination but also 
attempts at further increasing treatment efficacy and understanding mechanisms of change. 
One way of approaching these issues is through the study of mediators of treatment effect; 
i.e., variables which change subsequent to an intervention and prior to change in an outcome 
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241. There is preliminary evidence that the effect of G-ICBT on core features of health anxiety 
(disease conviction and fear and worry about illness) is mediated by lowered perceived risk 
of disease, less attention devoted to symptoms, and reduced intolerance of uncertainty, but 
not perceived awfulness of disease 242. Based on a more loose conceptualisation of mediation 
as purely an interaction of growth curves, the waiting-list controlled effect of FTF-CBT on 
health anxiety also appears to be mediated by a reduction in dysfunctional attributions of 
bodily symptoms 184, and the effect G-ICBT over and above behavioural stress management 
on health anxiety appears to be mediated by an increase in non-reactivity to inner experiences 
243; the ability to experience emotions, thoughts, and physical sensations without reacting on 
them 244. 
1.2.8 Cost-effectiveness and cost-utility 
Cost-effectiveness refers to the study of effects in relation to costs, in the comparison of 
possible courses of action 245. Most cost-effectiveness analyses are based on the incremental 
cost-effectiveness ratio (ICER), defined as the difference in condition effects divided by the 
difference in condition costs 245. Effects can be measured in various ways, either with highly 
disease-specific measures or through the use of health measures intended to be meaningful 
regardless of the condition under study (i.e., cost-utility analysis) 246. Quality-adjusted life 
years (QALYs), calculated as mean quality of life multiplied by years, is the most widely 
used measure of this sort 247. Costs can be calculated from the perspective of a wide variety of 
stakeholders, such as from a societal-, health care-, or clinic’s perspective. Given that ICER 
point estimates can be difficult to interpret 248, it is also commonplace to report sensitivity 
analyses based in Monte Carlo simulation or bootstrapping 245. 
The cost-effectiveness of FTF-CBT for severe heath anxiety has, to my knowledge, been 
studied based on data from two RCTs. First, a pilot study of FTF-CBT in a genitourinary 
medicine clinic reported an ICER of £ 33 per point reduction on the HAI up to the one-year 
follow-up, as based on a health care perspective and compared to treatment as usual 210. 
Second, a large multicentre trial (N=445) investigated the cost-effectiveness of FTF-CBT 
delivered by non-expert clinicians, compared to treatment as usual, for patients in medical 
clinics. The results were suggestive of cost-effectiveness in terms of effect on health anxiety 
(ICER: £ 56 per point reduction on the HAI up to the two-year follow-up) and also suggestive 
of cost-utility as based on the commonly cited guideline of £ 20 000 per QALY 249 put forth 
by the British National institute for health and care excellence (societal perspective ICER: £ 
14 169 per QALY, up to the two-year follow-up) 86. 
The cost-effectiveness of G-ICBT has also been studied in two clinical trials. First, one study 
found that G-ICBT was more cost-effective than an attention control condition (ICER: £ -
1 244 per additional case in remission up to the post-treatment assessment), and also found 
evidence of cost-utility (ICER: £ -6 533 per QALY up to the post-treatment assessment), as 
based on a societal perspective 218. A second study compared G-ICBT to internet-based 
behavioural stress management, and presented a cost-effectiveness ICER of $ 2214 per 
additional case of clinically significant improvement up to the post-treatment assessment, and 
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a cost-utility ICER of $ 10 000 per QALY up to the post-treatment assessment, as based on a 
societal perspective 250. Available studies thus suggest that CBT, especially in the minimal-
contact format, has the potential to be a cost-effective treatment for severe health anxiety.  
1.2.9 Availability of CBT 
Most patients with severe health anxiety prefer psychological treatment over medications 251, 
but there is a shortage of qualified therapists 252, the availability of CBT is poor 7, and 
treatment for severe health anxiety is seldom offered 253. The availability of CBT is also 
unevenly distributed between geographical regions, as illustrated by both a recent British 
study 254 and figures from the Swedish National board of health and welfare 252. Because 
minimal-contact treatments have the potential to facilitate treatment dissemination and 
dramatically improve the availability of psychological treatment for common psychiatric 
conditions, further development of such treatment formats has been identified by experts as 
an important research topic in clinical psychology 7. 
1.2.10 Advantages of minimal-contact treatment formats 
An important advantage of minimal-contact CBT (e.g., G-ICBT, U-ICBT, and BIB-CBT) 
compared with conventional FTF-CBT is that less (or no) therapist time is needed. For 
example, a typical finding is that G-ICBT requires approximately 10 minutes of therapist 
time per patient and week 88. This not only has the potential to reduce treatment costs, but 
also makes it possible to treat more patients; especially in health care sectors where there is a 
shortage of clinicians with adequate training in CBT. The highly structured text-based format 
also reduces the risk that therapists deviate from the intended treatment (“therapist drift” 255). 
Minimal-contact CBT may potentially have a democratising effect on mental health care. 
Without the need for face-to-face meetings, social stigma is less likely to interfere with health 
care seeking. Because the patient is not required to travel to a clinician, individuals living in 
rural areas, those living far from clinics, and those who are not fluent in the majority language 
may still be offered treatment. Because communication with a therapist is either non-existent 
or typically done though an email-like system, there is also usually no need to work with the 
treatment during any particular time of the day, meaning that the treatment is easier to access 
for patients with irregular schedules. 
Last but not least, there may be benefits for the therapist, who is free to communicate with the 
patient at any time, without the need to schedule appointments. If the treatment is delivered 
online, there is also the advantage that self-rated questionnaires for symptom measurement 
can be seamlessly integrated with the treatment platform. Because the therapist is able to treat 
significantly more patients, and geographical distances are no barrier to treatment, G-ICBT 
may offer an efficient way of achieving certain types of clinical expertise, perhaps especially 
with regard to rare conditions. This, in turn, may have beneficial effects also for the patient. 
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1.2.11 Summary and current directions 
Cognitive behaviour therapy (CBT) is the gold standard psychological treatment for severe 
health anxiety, and usually includes components of self-monitoring, psychoeducation, and 
exposure or cognitive restructuring techniques. Traditionally CBT has taken the form of FTF-
CBT, but the availability of this type of treatment is poor. Recent years has seen increased 
interest in minimal-contact treatment formats such as therapist-guided internet CBT (G-
ICBT), unguided internet CBT (U-ICBT), and cognitive behavioural bibliotherapy (BIB-
CBT). Compared with FTF-CBT, minimal-contact CBT has several advantages, including 
that much less therapist time is needed per treatment. Prior to the present project, it was 
however unclear if unguided minimal-contact CBT such as U-ICBT and BIB-CBT can be 
efficacious for severe health anxiety. As to G-ICBT, this format had been found to produce 
large effects on health anxiety, but had never been directly compared to FTF-CBT in an RCT. 
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2 AIM OF THE THESIS 
 
The general aim of this thesis was to develop and evaluate new technologies to facilitate the 
assessment of common diagnoses, and increase the availability of efficacious treatments, for 
severe health anxiety. Specific aims were: 
 
I. To develop, and evaluate the inter-rater reliability of, a structured clinical 
interview for diagnostic assessment of DSM-5 SSD and IAD. We hypothesised 
that the inter-rater reliability of the interview would be adequate. 
 
II. To investigate the short-term efficacy of G-ICBT, U-ICBT, and BIB-CBT for 
severe health anxiety. We hypothesised that all three treatments would be more 
efficacious than a waiting-list control condition. A secondary aim was to conduct 
a tentative comparison of the three treatments. 
 
III. To investigate the long-term efficacy, cost-effectiveness, and cost-utility of G-
ICBT, U-ICBT, and BIB-CBT for severe health anxiety. We hypothesised that the 
symptom levels of all three treatments groups would remain stable up to the one-
year follow-up, and that all three treatments would be more cost-effective than a 
waiting-list condition, as assessed over the main phase of the trial. A secondary 
aim was to compare the treatments in terms of efficacy and cost-effectiveness. 
 
IV. To investigate if G-ICBT is non-inferior to FTF-CBT for severe health anxiety. 
We hypothesised that G-ICBT would not be inferior to FTF-CBT, and that the 
symptom levels of both treatment groups would remain stable up to six months 
after treatment. 
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3 STUDIES 
3.1 STUDY I: THE HEALTH PREOCCUPATION DIAGNOSTIC INTERVIEW: 
INTER-RATER RELIABILITY OF A STRUCTURED INTERVIEW FOR 
DIAGNOSTIC ASSESSMENT OF DSM-5 SOMATIC SYMPTOM DISORDER 
AND ILLNESS ANXIETY DISORDER  
3.1.1 Background and aims 
With the DSM-5, two new diagnoses, SSD and IAD, were introduced for sufferers of severe 
health anxiety. The aim of Study I was to develop a structured diagnostic interview for the 
assessment of DSM-5 SSD and IAD, and to evaluate its inter-rater reliability. The primary 
hypothesis was that the inter-rater reliability in discriminating between SSD, IAD and non-
diagnostic cases would be adequate. 
3.1.2 Methods 
Initial development of the Health Preoccupation Diagnostic Interview (HPDI) was based on 
expert consensus and pilot testing in patients at the mental health division of a primary care 
clinic. Diagnostic interviews based on the HPDI were then conducted with applicants for a 
clinical trial of severe health anxiety (n=52), and with matched healthy controls (n=52) 
before, based on the recorded interviews, separate diagnostic assessments were done by 
another, blinded, clinician. Cohen’s κ was the primary measure of inter-rater agreement. 
3.1.3 Results 
The inter-rater reliability of the HPDI in the assessment of SSD and IAD was moderate to 
almost perfect (κ=.85 for the pooled sample). As for the diagnostic specifiers, the reliability 
of the SSD severity and persistency specifiers were estimated to be slight to fair (κ=.08–.30), 
the reliability of the SSD pain specifier was moderate (κ=.45), and there was perfect 
agreement on the IAD care-seeking specifier (κ=1). Disagreement on diagnosis was primarily 
related to the severity of somatic symptoms, and the differential diagnosis of panic disorder. 
3.1.4 Personal reflection 
Study I gave me insights into both psychometric methods and the day-to-day practice and 
pitfalls of clinical research. This study also gave me practical experience of the importance of 
open and frequent, scheduled and non-scheduled, communication between those involved in 
the same research project. 
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3.2 STUDY II: EXPOSURE-BASED COGNITIVE-BEHAVIOURAL THERAPY VIA 
THE INTERNET AND AS BIBLIOTHERAPY FOR SOMATIC SYMPTOM 
DISORDER AND ILLNESS ANXIETY DISORDER: RANDOMISED 
CONTROLLED TRIAL 
3.2.1 Background and aims 
Prior to Study II, G-ICBT had been found to be efficacious with specific effects on severe 
health anxiety 88, 193, but CBT without a therapist had only been studied in pilot trials with 
significant limitations 235, 236. The primary aim of Study II was to evaluate if minimal-contact 
CBT for severe health anxiety is efficacious not only in the form of G-ICBT, but also if 
delivered without therapist support or as book-form bibliotherapy. This was also the first 
clinical trial of CBT for severe health anxiety to recruit participants based on DSM-5 SSD 
and IAD. We hypothesised that G-ICBT, U-ICBT and BIB-CBT would be more efficacious 
than a waiting-list control (WLC). Secondary aims were to investigate if symptom levels 
were sustained six months after treatment, and to conduct a preliminary comparison of the 
effects of G-ICBT, U-ICBT, and BIB-CBT. 
3.2.2 Methods 
We recruited 132 participants with severe health anxiety operationalised as SSD or IAD, who 
were randomised in a 1:1:1:1 ratio to 12 weeks of G-ICBT, U-ICBT, BIB-CBT, or WLC. All 
treatments were primarily based on ERP, and were identical except for the administration 
format. Primary outcome was the time*group interactions indicative of waiting-list controlled 
change on the HAI in mixed linear models, from pre- to post-treatment. Remission rates were 
estimated based on clinically significant improvement 216.  
3.2.3 Results 
G-ICBT, U-ICBT, and BIB-CBT were more efficacious than the WLC, and improvements in 
the treatment groups were maintained up to six months after treatment. The waiting-list 
controlled effects were large and similar (d=0.80–1.27), and there was no significant 
difference in symptom course between the three active treatments (Ps=.432–.715). 
Approximately 47–53% of patients in CBT were in remission at the 6-months follow-up. 
3.2.4 Personal reflection 
The greatest challenge of Study II has been the communication of results and assessment of 
clinical implications. This trial was a hybrid between a feasibility and dismantling trial. While 
the primary aim was to assess if CBT without a therapist (i.e., U-ICBT and BIB-CBT) is an 
efficacious and feasible treatment alternative for severe health anxiety, the trial also allowed 
for comparison against the G-ICBT condition which only differed from the U-ICBT in terms 
of therapist involvement. It is important to recognise that the trial was powered to allow for 
comparisons against the WLC, but that it was underpowered to study small to medium sized 
effects between the treatments based on null-hypothesis testing.  
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3.3 STUDY III: COST-EFFECTIVENESS AND LONG-TERM FOLLOW-UP OF 
THREE FORMS OF MINIMAL-CONTACT COGNITIVE BEHAVIOUR 
THERAPY FOR SEVERE HEALTH ANXIETY: RESULTS FROM A 
RANDOMISED CONTROLLED TRIAL 
3.3.1 Background and aims 
Prior to Study III, the long-term efficacy and cost-effectiveness of G-ICBT for severe health 
anxiety had been demonstrated 218, but little was known about unguided CBT. The primary 
aim of Study III was to investigate the cost-effectiveness and long-term effects of three forms 
of minimal-contact CBT on severe health anxiety. We hypothesised that G-ICBT, U-ICBT, 
and BIB-CBT would all be more cost-effective than the WLC, and that improvements would 
be maintained up to the one-year follow-up. A secondary aim was to conduct a tentative 
comparison of the cost-effectiveness and long-term efficacy of the three active treatments. 
3.3.2 Methods 
Study III was based on the same RCT as Study II. The analysis of effects in relation to costs 
was based on the ICER (1.2.8), and separate analyses were done of remission rates (i.e., cost-
effectiveness) and QALYs (i.e., cost-utility). Separate analyses were also done from the 
perspective of society, health care, and the clinic, respectively. QALYs were estimated based 
on the EuroQol-5D 256 with Swedish norms 257, and remission was estimated based on the 
reliable change index 216 and an established cut-off point for identifying clinical cases of 
severe health anxiety based on the HAI 258. Costs were estimated based on the Trimbos and 
institute of medical technology assessment cost questionnaire for psychiatry 259. Change in 
health anxiety over the follow-up period was modelled with linear mixed effects models. 
3.3.3 Results 
G-ICBT, U-ICBT, and BIB-CBT were more cost-effective than the WLC, given that society 
is willing to pay up to £ 416 per case of severe health anxiety in remission over the 12-week 
treatment period. Up to the one-year follow-up, health anxiety levels were maintained or 
further lowered, without significant differences between the treatments. If the willingness to 
pay for additional effects is very low or zero, BIB-CBT is probably more cost-effective than 
G-ICBT and U-ICBT as modelled from a societal perspective, up to one year after treatment. 
3.3.4 Personal reflection 
In working with Study III, it became increasingly clear to me that an obstacle in health 
economics is the scarcity of previous work on which to base value judgments with regard to 
cost-effectiveness, and especially under scenarios not based on QALYs. My strategy in 
addressing the challenge of missing data as well as the lack of common guidelines for the 
conduct of cost-effectiveness analyses was to present a series of analogous analyses, each 
based on different assumptions about the data, and perspectives on cost-effectiveness an cost-
utility. My hope is that this will enable the reader to get a more nuanced and multifaceted 
understanding of the outcome of the trial. 
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3.4 A PRIMER ON NON-INFERIORITY TRIALS 
Most clinical trials are so called superiority trials, designed to test the hypothesis that one 
condition (e.g., treatment) is more effective than another. In most cases, this is investigated 
based on null hypothesis significance testing, i.e., estimation of the probability of an observed 
outcome given that the null hypothesis is true. If, given that the null hypothesis is assumed to 
be true, the observed outcome is highly improbable (P<.05), this justifies rejection of the null 
hypothesis and the alternative hypothesis is corroborated. 
Another scenario is when the hypothesis is that one condition is at least as effective as – i.e., 
non-inferior to – another. This type of hypothesis is common in cases where a new treatment 
is developed to address a problem for which there already exists another more established 
intervention. In a conventional superiority framework, null hypothesis significance testing 
does not allow for this type of hypothesis to be investigated because the absence of a true 
effect is per definition the null hypothesis, and cannot be proven. Regardless of sample size, a 
non-significant difference between two groups could just be due to insufficient power.  
The idea behind a non-inferiority trial is that instead of proving the absence of a true effect, it 
is possible to demonstrate with sufficient certainty that there is no true between-group effect 
large enough to be of any practical interest. Therefore, prior to the analysis of non-inferiority, 
it is necessary to decide on the smallest true effect that would be of clinical interest. The 
value chosen for this so called non-inferiority margin (Δ) should be such that if the true effect 
is smaller than Δ, it is not clinically significant. This is usually understood to mean that no 
point on the confidence interval for the difference between conditions should be indicative of 
an effect equal to Δ or larger in favour of the more established treatment. In pharmaceutical 
research, a common recommendation is for Δ to be no larger than half of the placebo-
controlled effect of the established treatment 260. 
Most guidelines for non-inferiority trials recommend that the main analysis is repeated both 
from an intention-to-treat (ITT) perspective (i.e., with data from all participants of the trial), 
and a per-protocol (PP) perspective (i.e., with data from treatment completers only) 261. This 
is because, in the non-inferiority framework, both perspectives have clear advantages and 
disadvantages. In the ITT analysis, because all participants are included in the analysis, both 
groups are representative of the original population from which they were randomly sampled, 
and there is control over confounders of the effect of treatment condition on the outcome. 
However, unlike in superiority trials, ITT analysis is not a conservative method because 
should adherence be poor, this could potentially lead to the fabrication of “non-inferiority” 
because the course of non-adherent participants is likely to be similar regardless of condition. 
The PP analysis is the mirror image to its ITT equivalent, and has the advantage that all 
participants in the analysis were exposed to the intended protocol, but the disadvantage that 
because non-adherent participants were excluded from analysis, there could be an issue of 
selection bias or confounding 260. 
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3.5 STUDY IV: COGNITIVE BEHAVIOUR THERAPY FOR HEALTH ANXIETY 
VIA THE INTERNET AND AS FACE-TO-FACE TREATMENT: A 
RANDOMISED CONTROLLED NON-INFERIORITY TRIAL 
3.5.1 Background and aims 
The most well-established psychological treatment for severe health anxiety is FTF-CBT, but 
access to FTF-CBT is poor. G-ICBT is a new treatment format which enables wider 
dissemination of evidence-based treatment. Less therapist time is needed per treatment, and 
the intervention is more flexible with regard to time and geographical obstacles. G-ICBT is 
the type of minimal-contact CBT that has been most convincingly found to be efficacious in 
the treatment of severe health anxiety, but it has never been compared directly to FTF-CBT. 
The aim of study IV was to investigate if G-ICBT is non-inferior to (i.e., at least as 
efficacious as) FTF-CBT in the treatment of severe health anxiety, and we hypothesised that 
G-ICBT would be non-inferior to FTF-CBT in the reduction of health anxiety. A secondary 
aim was to compare the effect of G-ICBT and FTF-CBT on secondary symptoms of general 
anxiety, depression, and functional impairment. 
3.5.2 Methods 
Study IV presents the main outcome of a randomised controlled non-inferiority trial based at 
a primary care clinic, where patients (N=204) were randomised to G-ICBT or FTF-CBT. 
Treatments were 12 weeks long and identical except for the administration format. Primary 
outcome was based on the one-sided confidence interval for the coefficient of the group*time 
interaction on the 18-item SHAI, which was measured with weekly intervals over the 
treatment period. A non-inferiority margin (Δ) of 0.3 d, equivalent to 2.25 points on the 
SHAI, was chosen based on (1) the controlled effect of FTF-CBT against waiting-list and 
treatment as usual conditions 173, (2) evidence pertaining to patients’ beliefs about clinical 
significance 262, and (3) clinical judgment. Non-inferiority was assessed both from an ITT and 
PP perspective. Secondary outcomes were also based on self-rated questionnaires. 
3.5.3 Results 
The modelled difference in change between G-ICBT and FTF-CBT over the treatment period 
was -0.0003 points favouring G-ICBT (Figure 5), and the upper limit of the one-sided 95% 
confidence interval was 1.9774 in favour of CBT as based on intention-to-treat data, and 
2.1717 in favour of CBT as based on per-protocol data. Both upper bounds for the confidence 
interval were thus lower than the non-inferiority margin (Δ) of 2.25, indicating that G-ICBT 
is non-inferior to FTF-CBT. The difference in effect on health anxiety was not moderated by 
treatment preference (P=.122), baseline health anxiety (P=.062), or the path of referral (i.e., 
routine care vs. not routine care; P=.357), and there were also no significant differences in 
effect on secondary symptoms. 
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Fig. 5. Main outcome of Study IV. Observed and modelled change in health anxiety over 12 weeks in treatment, 
by treatment group. Estimates are based on the fixed portion of mixed effects models and intention-to-treat data 
(i.e., all patients in the study were included). Error bars are omitted for clarity of presentation. CBT=individual 
cognitive behaviour therapy. G-ICBT=therapist-guided internet cognitive behaviour therapy. SHAI=18-item 
Short Health Anxiety Inventory. 
3.5.4 Personal reflection 
Study IV is without doubt the part of this project which demanded the most amount of hard 
work, and also the trial in which I feel that I was able to work more or less as an independent 
researcher. For me, amongst the most rewarding aspects of this trial was to offer supervision 
of others involved in the project, and to ensure that high treatment fidelity was achieved.  
Please note that, in an attempt to avoid jargon, the manuscript detailing the proceedings of 
Study IV refers to severe health anxiety (i.e., the clinically significant condition) as “health 
anxiety” which, in this thesis, is otherwise used to denote the dimensional trait. Note also that 
the same manuscript refers to the 18-item Short Health Anxiety Inventory (SHAI) simply as 
the “Health Anxiety Inventory” (“HAI”). 
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3.6 ETHICAL CONSIDERATIONS 
All four studies here presented were approved by the regional ethics review board of 
Stockholm (2013/375-31/5, 2014/1530-31/2), proceeded in line with the declaration of 
Helsinki 263 and good clinical practice 264, and followed Swedish and European jurisdiction 
for the management of data and personal information. Four particularly important ethical 
concerns were: (1) the implementation of informed consent, (2) the risk of adverse outcomes, 
(3) the management and presentation of data, (4) and transparency of the research process. 
In both trials here reported, informed consent was given via a minimalistic online form. Both 
the phrasing of the information given, and the method of administration, was described in the 
ethics application and submitted for review by the ethics review board. The text presented to 
the study applicants clearly stated that participants could withdraw their consent at any time. 
In order to ensure the wellbeing of all participants, symptoms were continuously monitored 
through the course of both trials. In cases of severe deterioration or suicidality, participants 
were contacted and referred to routine health care services. The implementation of a waiting-
list condition in Study II–III was seen as justified because so little was known about unguided 
treatments for severe health anxiety, and more information could potentially be used to help 
those in need. It was also ensured that participants were crossed over to an active treatment 
after the main phase of the trial (see 4.6.3). 
All studies involved the management of sensitive information, and a number of precautions 
were therefore taken to safeguard the personal integrity of all participants. The web-based 
online treatment platform employed two-factor authentication, all data traffic was protected 
through the use of 128-bit encryption, and completed symptom questionnaires could only be 
accessed by researchers working with the trial. Data were stored on secure servers and in 
locked journal cabinets. Whenever results of the trial were communicated, these results were 
anonymised and analysed at group level. 
One of several threats to the transparency of clinical research is publication bias, i.e., that the 
probability of publication is contingent on the outcome of the study. In an attempt to be as 
transparent as possible with the method and proceedings of the trials, both were preregistered 
at ClinicalTrials.gov (NCT01966705, NCT02314065), and all publications based on the trials 
included a reference to the corresponding online protocol.  
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4 GENERAL DISCUSSION 
4.1 SUMMARY OF FINDINGS 
This thesis presents new evidence pertaining to the assessment and treatment of severe health 
anxiety. A preliminary finding is that DSM-5 SSD and IAD can be reliably assessed based on 
a new structured diagnostic interview (i.e., the HPDI). In addition, two RCTs contributed to 
the development and dissemination of treatments for severe health anxiety. First, it was found 
that minimal-contact CBT – also without a therapist – can be an efficacious and cost-effective 
treatment for severe health anxiety. Second, therapist-guided internet CBT (G-ICBT) was 
found to be at least as efficacious as individual face-to-face CBT (FTF-CBT) for severe 
health anxiety. At follow-up, the effects of all treatments under investigation were also found 
to be sustained over time. I believe that the findings of Study II–IV have important clinical 
implications for the treatment and management of severe health anxiety, as detailed below. 
4.2 ARE DIAGNOSES OF SSD AND IAD BASED ON THE HEALTH 
PREOCCUPATION DIAGNOSTIC INTERVIEW (HPDI) SUFFICIENTLY 
RELIABLE? 
It appears to be possible to diagnose DSM-5 SSD and IAD based on the HPDI with adequate 
inter-rater reliability, though the assessment of the SSD persistency and severity specifiers are 
probably not sufficiently reliable (Study I). To my knowledge, there exists only one other 
published study of the inter-rater reliability of a diagnostic procedure for SSD and IAD. This 
study was based on the Anxiety and Related Disorders Interview Schedule for DSM-5, and 
the inter-rater reliability of SSD and IAD was largely on par with the results of Study I. Also 
as in Study I, the most common reason for non-concordance was disagreement over the 
severity of somatic symptoms 52. In addition, one study has presented adequate inter-rater 
reliability figures for SSD 54, and another study has presented adequate inter-rater reliability 
of IAD 265, as based on procedures where the two disorders were not assessed in parallel. 
A limitation of Study I was that only diagnoses from two clinicians could be compared, 
which means that the agreement over diagnoses was conflated with the agreement of two 
specific clinicians. Another limitation was that the number of patients with IAD was small 
(n=7). It is thus too early to say with certainty how reliable the HPDI would be in the hands 
of most clinicians, and there is a need for further studies with other clinicians and samples.  
In clinical practice, the utility of SSD and IAD as diagnoses in severe health anxiety is not 
clear. My suspicion is that, in line with data published after initiation of the present project 52, 
87, SSD is typically predictive of a slightly larger effect of CBT on health anxiety, but that 
this effect can be explained by slightly higher mean baseline health anxiety. In a pooled 
analysis based on data from all patients in CBT in Study II–IV (N=303), the effect of having 
IAD only bordered on being significant (P=.050), with a small and not clinically significant 
effect size. If baseline health anxiety was included as a predictor in the model, the effect of 
diagnosis was no longer near-significant (P=.231). Thus, if there is a true effect of diagnosis 
(SSD vs. IAD) as a moderator of the effect of CBT on health anxiety, it is probably not very 
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important, and when the level of health anxiety is known, SSD and IAD may not add much 
clinically useful information. Nevertheless, the HPDI allows for further exploration into this 
and other hypotheses pertaining to DSM-5 SSD and IAD. 
4.3 IS UNGUIDED CBT EFFICACIOUS FOR SEVERE HEALTH ANXIETY? 
As hypothesised, all three minimal-contact treatments (i.e., G-ICBT, U-ICBT, and BIB-CBT) 
had large waiting-list controlled effects on health anxiety, and also small to medium sized 
effects on secondary symptoms of general anxiety, depression, and functional impairment 
(Study II–III). This indicates that the involvement of a therapist is not necessary to achieve 
large effects in CBT for severe health anxiety, and that unguided CBT can have mean effects 
similar those of FTF-CBT (1.2.4.1). Strengths of Study II were the randomised controlled 
design, and the fact that all therapies were based on the same treatment content. The main 
finding that U-ICBT and BIB-CBT can be highly efficacious is in line with previous work 
demonstrating that unguided treatments can be efficacious for common psychiatric disorders 
266, though the effect sizes of U-ICBT and BIB-CBT were slightly larger than anticipated. 
As to long-term effects, improvements made in G-ICBT, U-ICBT and BIB-CBT were 
sustained over time. This is in line with a previous study of G-ICBT for severe health anxiety 
218, and also studies of BIB-CBT for depression, obsessive-compulsive disorder, and social 
anxiety disorder 238-240. The long-term course was also at least as promising as that seen in 
most follow-up studies of FTF-CBT for severe health anxiety (1.2.4.1). 
The large effects of these unguided treatments ought to be generalised with caution, due to 
the highly structured treatment context. It was for example the case that participants knew 
that the trial had a specific end date, and all participants also received weekly SMS reminders 
to complete their online assessments, which most likely had a positive effect on treatment 
adherence. Although the prerequisites for the efficacy of pure self-help treatments need be 
studied further, Study II clearly shows that unguided minimal-contact CBT can be highly 
efficacious for severe health anxiety given the right circumstances. 
4.4 IS UNGUIDED CBT COST-EFFECTIVE FOR SEVERE HEALTH ANXIETY? 
As hypothesised, G-ICBT, U-ICBT, and BIB-CBT were more cost-effective than the WLC, 
as assessed over the 12-week treatment period (Study III). It was also found that BIB-CBT 
probably is the most cost-effective treatment format if the willingness to pay is low (i.e., if 
society is not willing to pay for additional beneficial effects). Important strengths of Study III 
were that several minimal-contact treatments could be compared, and that various scenarios 
were explored with regard to costs and assumptions about the data.  
The main outcome was similar to that of an earlier study which found that G-ICBT was more 
cost-effective than an attention control condition 218. Both in that study and Study III, cost-
effectiveness versus the non-treatment control was more a question of a difference in effect, 
than a difference in costs. In both studies, the reduction in monthly costs was larger in CBT 
than in the no-treatment group, but in Study III the cost of G-ICBT and BIB-CBT outweighed 
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the advantage in gross total costs. It is not unlikely that, had the patients been followed over a 
longer time-frame, there had been a net cost advantage of all forms of CBT versus the WLC. 
Nevertheless, the net costs of all forms of minimal-contact CBT investigated were very small, 
and especially considering their apparent efficacy.  
Under most scenarios, none of the treatments showed promise in terms of cost-utility, which 
is also in line with a previous study of FTF-CBT 267. In Study III, the effects on QALYs were 
small, and it thus appears that the primary justification for implementation of the type of CBT 
here investigated should be its effect on health anxiety rather than effects on QALYs. One 
possible explanation for the small effect on QALYs is that the measure is heavily dependent 
on physical, as opposed to psychosocial, impairment, at least if based on the EuroQol-5D 256 
on which one of five items concerns mobility (i.e., the ability to walk and move freely) and 
one concerns self-care (primarily the ability to take care of personal hygiene and get dressed), 
which are relatively unaffected domains of functioning in severe health anxiety 113. 
Limitations of Study III were the relatively high proportion of missing data at the one-year 
follow-up, and that the WLC was crossed over to an active treatment. Whether or not the 
treatments were more cost-effective also depends on the willingness to pay, and there exists 
no recognised criterion for the cost-effectiveness of interventions for severe health anxiety. 
The choice of a criterion for cost-effectiveness is not solely determined by empirical data, but 
is also by ethical, ideological, and practical considerations. 
4.5 IS G-CIBT NON-INFERIOR TO FTF-CBT FOR SEVERE HEALTH ANXIETY? 
As hypothesised, G-ICBT is at least as efficacious as FTF-CBT in the treatment of severe 
health anxiety. That is, for the majority of patients with severe health anxiety, it is likely that 
if FTF-CBT works, G-ICBT works as well. This finding is in line with previous comparisons 
of G-ICBT and FTF-CBT for other psychiatric disorders 234, and underscores the potential of 
G-ICBT to increase the availability of CBT for severe health anxiety on a wider scale. To my 
knowledge, Study IV is yet the largest randomised controlled comparison of individual FTF-
CBT to G-ICBT for any psychiatric or somatic condition 234. 
The effects of G-ICBT on severe health anxiety have now been investigated in five RCTs, 
and if one is willing to consider the provision of fortnightly online educational content as a 
psychological treatment 87, it could be argued that the treatment format meets the American 
Psychological Association criteria for an empirically supported treatment (i.e., the highest 
level of evidence). Based on a meta-analytic approach, the pooled within-group effect of G-
ICBT on health anxiety has been 1.74 g (Table 3), comparable to 1.64 of FTF-CBT (1.2.4.1). 
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Non-inferiority was seen despite the fact that patients rated the strength of their relationship 
with their therapist slightly lower in G-ICBT than in FTF-CBT. In line with Study II–III, this 
is support for the idea of that there may be characteristics of G-ICBT, perhaps including the 
highly-structured treatment format, which compensate for a weaker therapeutic alliance. 
Strengths of Study IV included the high treatment fidelity, that therapists were balanced over 
the two conditions, that the treatments were delivered in a routine care environment at a 
primary care clinic, that 13 measurement points and mixed models allowed for stable models 
of change with little room for prediction error 268, and that the main outcome was the same 
regardless of whether the analysis was based on an ITT or PP framework. Another finding 
which speaks for the internal validity of Study IV is that in both G-ICBT and FTF-CBT, there 
was a dose-response relationship between adherence (i.e., the number of modules or sessions 
completed) and effect on health anxiety.  
A limitation of Study IV was that only approximately one third of the patients were recruited 
through routine care. Notably, however, the recruitment path did not appear to moderate the 
effect of CBT on health anxiety. For a detailed discussion of generalisability, see 4.6.1–4.6.2. 
There was also no diagnostic assessment at treatment termination, but this is seldom seen in 
trials treatment for severe health anxiety, see 4.6.4 22. 
4.6 GENERAL METHODOLOGICAL ISSUES AND POTENTIAL THREATS TO 
VALIDITY 
4.6.1 On the operationalisation of severe health anxiety and generalisability 
to DSM-IV hypochondriasis 
Unlike in previous trials by our research group where the inclusion of participants was based 
on a diagnosis of DSM-IV hypochondriasis 88, 193, inclusion in Study II–IV was based on 
DSM-5 SSD and IAD. This was because the DSM-5 is intended to replace the DSM-IV, the 
SSD and IAD diagnoses were intended for individuals with severe health anxiety, and the 
DSM is the most widely used taxonomy for research and work with psychiatric disorders. 
Based on the comparison of diagnostic criteria (Table 1), it is evident that SSD and IAD do 
not correspond precisely to DSM-IV hypochondriasis. The SSD diagnosis is relatively broad, 
and it is possible to meet full criteria for SSD without meeting full criteria for DSM-IV 
hypochondriasis (1.1.3.2). This may be either (a) due to an excessive preoccupation with 
somatic symptoms without a fear of having or acquiring as severe illness, (b) due to a shorter 
duration (i.e., while DSM-IV hypochondriasis requires a duration of at least six months, the 
SSD criterion is more vague), or (c) because there has been no medical reassurance (e.g., due 
to phobic avoidance of medical evaluation). Moreover, it is also possible to meet full criteria 
for IAD without meeting full criteria for DSM-IV hypochondriasis, primarily because in IAD 
the fear of illness need not be based on the misinterpretation of physical symptoms. 
Nevertheless, my impression is that the samples presented in this thesis were remarkably 
similar to the samples of the two previous trials of G-ICBT for severe health anxiety by our 
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research group, where inclusion was instead based on DSM-IV hypochondriasis (Table 4). 
This is probably because most other eligibility criteria were kept unchanged, and all trials 
employed more or less the same recruitment strategy. All four trials of G-ICBT were 
advertised to clinicians and the public under the heading "Do you worry a lot about your 
health?", a key item of the WI 73, which is widely acknowledged as a valid measure of health 
anxiety. All advertisements clearly stated that the trial was intended for individuals with "a 
persistent fear of being ill or acquiring a disease". It was also explained to all applicants that 
treatment would focus on a fear of having or acquiring a serious health condition, as opposed 
to, for example, chronic pain.  
For sake of validation, in addition to the assessment of SSD and IAD, in the present project 
we also assessed DSM-IV hypochondriasis, and found it to be present in approximately 9 of 
10 patients (Table 4). In Study IV, the most common reason for not meeting full criteria for 
hypochondriasis (n=13) was that the patient had not been given medical reassurance (n=7), 
followed by too short duration (n=5), and that the fear was not based on the misinterpretation 
of bodily symptoms (n=1). Thus, the reason that the participants did not meet full criteria for 
DSM-IV hypochondriasis was not that they did not fear having or acquiring a severe illness. 
Rather, the type of patient that was recruited for the present project, but not the two previous 
trials of G-ICBT by our research group, was either characterised by the avoidance of health 
care, or a slightly shorter duration of severe health anxiety. This was confirmed during the 
latter half of Study IV, when the last 48 patients diagnosed with SSD were asked about their 
primary catastrophic belief (i.e., what they feared most) with regard to their symptoms. All 
these patients worried most either about disease and/or death, and not some other outcome. 
In a pooled analysis of all patients in CBT in Study II–IV (N=303), whether the patients met 
full criteria for DSM-IV hypochondriasis was not a predictor of the main outcome (P=.982). 
In summary, though results may not generalise to other forms of SSD where there is no fear 
of having or acquiring a severe health condition, it appears sensible to regard all patients from 
the present project and the two previous trials by the research group as having been sampled 
from the same population; one of individuals with severe health anxiety.  
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4.6.2 On the generalisability to routine care 
Another important question is that of generalisability to routine care, which is likely to vary 
much depending on the specific type of routine care. Patients with severe health anxiety are 
found throughout the health care system; in both primary care, specialised medical care, and 
psychiatric clinics, and it is thus conceivable to offer minimal-contact CBT for severe health 
anxiety in a large number of contexts. There are patient groups, such as very old patients, 
patients with substantial medical comorbidities, and patients with chronic pain, who were not 
well represented in the present project, and for whom it would not be sensible to generalise 
too broadly. However, even though 41–57% of applicants for Study II–IV were excluded 
from participation, many of the eligibility criteria, such as the requirement that patients meet 
criteria for a principal diagnosis indicative of severe health anxiety (responsible for 35% of 
exclusions), are also implemented in routine care, albeit in a more informal manner. Under 
many routine care scenarios, there is reason to suspect that patients and conditions have much 
in common with those in our studies (see Table 5).  
In order to evaluate the generalisability of Study II–IV, it is probably most informative to 
consider specific examples. One example of high relevance is the Internet psychiatry unit at 
Karolinska university hospital in Stockholm, which is a recognised provider of G-ICBT in 
routine care. The treatment format at this clinic is similar to that of Study IV, namely with 
referral from routine care or self-referral via the internet, face-to-face assessment, and 
approximately 10–12 weeks of treatment. The online treatment platform is also very similar 
to those used for the present project, and G-ICBT protocols for other anxiety disorders have 
made a successful transition from efficacy studies to routine care 270, 271. Even though patients 
at the Internet psychiatry unit are likely to have a lower average level of education than the 
patients of Study II–IV, most variables indicate that the effects of G-ICBT seen in the present 
project are likely to generalise to routine care at this clinic. 
Another possibility is to implement minimal-contact CBT for severe health anxiety in 
primary care. Based on comparison with two Scandinavian primary care samples (Table 5), 
the age and gender distribution as well as the comorbidity rates are likely to be similar in 
clinical practice, but as in the case of the Internet psychiatry unit, the proportion of patients 
with a high level of education is likely to be lower than in the trials presented here. 
Sociodemographic data has typically not been predictive of therapeutic outcome in RCTs of 
G-ICBT for severe health anxiety 220, 224. Likewise, a pooled analysis of all patients in CBT in 
Study II–IV (N=303) did not show any moderating effect of the level of education (P=.606). 
However, being married or having a partner was associated with a smaller treatment effect 
(3.0p on the 18-item SHAI over 12 weeks; P=.034), and so was being employed (2.3p on the 
18-item SHAI; P=.035). These effects are clinically significant (>2.25p) but small, and none 
remained statistically significant when (a) both predictors were included in the same model or 
(b) baseline health anxiety was included. Both effects were in a direction which suggests that 
the treatment effect might be larger (not smaller) in many routine care samples. There is thus 
reason to be optimistic about the generalisability of effects to many routine care contexts.  
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4.6.3 On the choice of a waiting-list control 
There is evidence to suggest that waiting-list conditions in the context of RCTs typically do 
not provide valid estimates of natural course 276. In other words, waiting-list controlled effects 
should typically not be interpreted as “change over and above that without treatment”. The 
implementation of a waiting-list control could also be ethically problematic, considering that 
approximately 17% of patients with common psychiatric disorders have been estimated to 
deteriorate if on a waiting-list 277.  
What, then, was the point of implementing a waiting-list condition in Study II–III? First, prior 
to the present project, no RCT had convincingly investigated the effects of U-ICBT or BIB-
CBT for severe health anxiety, and little was known about the effects of these interventions. 
The inclusion of a waiting-list was therefore an attempt to control for rudimentary processes 
such as regression towards the mean, without the risk of prematurely disregarding U-ICBT 
and BIB-CBT as viable treatment options should the treatments be inferior to another active 
treatment 278. Second, most previous RCTs of CBT for severe health anxiety have made 
comparisons against a waiting-list condition, and comparisons between the present studies 
and previous are thus facilitated. Third, there was the issue of convenience and cost. It was 
much easier and less demanding to implement a waiting-list condition than another active 
condition, attention control condition, or psychological placebo. A drawback of attention 
control and psychological placebo controls is also that these tend to differ much between 
trials, and that comparisons against such comparators may be at least as difficult to interpret.  
4.6.4 On the choice of outcomes 
A common critique of self-rated outcome measures is that it is unclear to which extent they 
correspond to more objective measures such as observer data, register data, biomarkers, and 
everyday functioning. While I agree that it had been informative to look at other measures as 
well, it is important to keep in mind that – in terms of the primary outcome of Study II and IV 
– self-rated questionnaires are the closest to a “gold standard” measure of health anxiety as 
one would come. This is the type of measure that has been used by most other clinical trials 
in the field 5, and it is also commonly used in epidemiological research on health anxiety 92, 93. 
An alternative to self-rated questionnaires had been to focus on continuous measures rated by 
a clinician. The general pattern in research on psychiatric disorders is however that self-rated 
and independently-rated outcomes tend to be highly correlated, the only clear difference 
being that independently-assessed measures typically show less variance 279, which makes 
standardised effect sizes larger, and gives slightly higher power to detect true differences in 
for example anxiety. However, the difference in precision is not large, and advantages of the 
self-report format include the ease of administration and the fact that comparisons against 
other clinical trials of CBT for severe health anxiety (1.2.4) are more straightforward. The 
repeated measurement which formed the basis for the precise statistical analysis of Study IV 
had been remarkably difficult and time-consuming if based on measures rated by a clinician. 
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A third possibility had been to use a psychiatric diagnosis as a criterion of remission and 
primary outcome of Study II and IV. Though this is the preferred approach in most of 
medical research, none of the two trials here presented incorporated diagnoses as outcome. 
While this is a limitation, I do not believe it to be as significant as it had been in the case of 
many other conditions. This is partly because, as explained in the introduction (1.1.3), there is 
no strong consensus on diagnostic criteria to capture severe health anxiety, and also because 
the division between pathological and non-pathological health anxiety is likely to be arbitrary 
22. The strong emphasis on continuous outcomes in the field of health anxiety is illustrated by 
the fact that out of the 13 RCTs surveyed under 1.2.4, only one 88 involved diagnostic 
assessment at post-treatment. The use of a dichotomous outcome had also severely impeded 
the statistical power of both trials, to the extent that it had not been possible for our research 
group to recruit the sample size needed for a non-inferiority trial of G-ICBT and FTF-CBT. 
4.7 WHAT DO THE NUMBERS MEAN? 
The results of the present project are almost universally presented in terms of numbers. For 
example, Study IV revealed that, based on the 18-item SHAI, the mean within-group change 
in G-ICBT from baseline to the post-treatment assessment was 1.65 d. But, from the patient’s 
perspective, what does such a number really mean? 
Before treatment, the average patient in Study II–IV suffered from a high level of health 
anxiety, typical of most clinical trials in the field. Most patients reported that they spent much 
time worrying about health, that they were “often afraid [of having] a serious illness”, and 
often worried about dying. Most indicated that they were “constantly aware of bodily 
sensations or changes”, and that they always worried about sensations or bodily changes 
without a clear cause. A clear majority of patients reported that they thought there was 
something wrong with their body, and that they found it difficult to believe their doctor when 
told that they had nothing to worry about. Most believed that their friends and family would 
characterise them as “a hypochondriac”. 
Before treatment, most patients stated that they were impaired in their daily work or studies, 
though typically not to a large degree and most were working full time. The effect of health 
anxiety was strong on emotional and social capabilities. (The typical patient reported being 
severely emotionally affected.) Most saw themselves as somewhat impaired in their capacity 
to engage in social activities, and moderately impaired with regard to their capacity to engage 
in family life and home activities. The typical patient had some, though not severe, difficulty 
sleeping, and scored above the cut-off for mild depression. Most reported planning their days, 
and abstaining from activities, in order to reduce or manage their physical symptoms. 
After treatment, the health anxiety level of the average patient was much reduced, though still 
around the clinical cut-off for severe health anxiety. Most reported that they still occasionally 
worried about their health, having a serious illness, and dying. They were also still sometimes 
aware of their bodily sensations or changes. The fear was however not as constant, and not as 
intense, as before treatment. Most responses changed from “often” to “sometimes”, “strong” 
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to “mild” and so on. This was also the case in terms of impairment and secondary difficulties. 
The average patient still reported being emotionally affected to a small degree, though most 
did not think that their health anxiety still interfered with their work or social life. The mean 
depression score was below the cut-off for mild depression, and after treatment, most patients 
no longer reported planning their days to reduce or manage their symptoms. This being said, 
the treatment response was very different from patient to patient. Whereas approximately 
every other patient in CBT was both reliably improved and scored below the cut-off for 
severe health anxiety at the post-treatment assessment, approximately one fourth was reliably 
improved but did not score below the cut-off, and one fourth was not reliably improved. 
4.8 CLINICAL IMPLICATIONS 
The work here presented has important clinical implications. First, the promising effects of 
CBT without therapist support (Studies II–III) indicate that this is likely to be an ideal 
treatment format for medical clinics that need offer treatment for severe health anxiety, but do 
not have the resources to conduct conventional FTF-CBT or G-ICBT. Both U-ICBT and 
BIB-CBT are experimental treatments for severe health anxiety, and effects need be 
replicated. The prospect of delivering efficacious psychological treatment for a psychiatric 
condition not too long ago considered difficult to treat even with conventional face-to-face 
therapies – and doing so entirely without the involvement of a therapist – is worthy of notice. 
G-ICBT appears to be non-inferior to FTF-CBT and should thus be regarded as a first-line 
treatment for severe health anxiety (Study IV). Considering the advantages of this treatment 
format, e.g., in terms of therapist time needed per treatment, and flexibility with regard to 
schedule and geography, further implementation and evaluation of G-ICBT in routine heath 
care is likely to be highly cost-effective, and has the potential to substantially increase the 
availability of CBT for those suffering from severe health anxiety. 
There is, however, still room for FTF-CBT. For some patients, G-ICBT may not be a feasible 
or practical intervention; an example being those with severe difficulties reading and writing. 
On the other hand, there are also patients likely to benefit more from G-ICBT than FTF-CBT; 
an example being those living far from health care clinics. Because the relative strengths and 
limitations of G-ICBT and FTF-CBT are likely to vary over settings, the most efficient way 
of delivering CBT (e.g., as G-ICBT, FTF-CBT, stepped care, or some sort of hybrid format) 
for severe health anxiety is likely to differ over sectors of the health care system. A reason to 
offer both treatment formats is also that it is yet unknown if non-responders in one type of 
treatment (e.g., G-ICBT) are likely to gain from a change of treatment format (e.g., from G-
ICBT to FTF-CBT) in the event of a second treatment attempt. 
As noted above, the availability of efficacious treatments for severe health anxiety is poor, 
and the reality for most patients with severe health anxiety is not that they are offered best-
practice FTF-CBT, or even psychological treatment of any kind. A broader implementation 
of G-ICBT is thus typically not a question of abandoning another best-practice treatment, but 
rather a transition to an efficacious treatment from no treatment at all. 
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4.9 SUGGESTIONS FOR FUTURE RESEARCH 
There are numerous viable areas of future research into the classification and treatment of 
severe health anxiety. One important line of research concerns the implementation and 
evaluation of G-ICBT and other forms of minimal-contact CBT for severe health anxiety in 
routine care. Another particularly important line of research concerns the large proportion of 
non-responders in all forms of CBT for severe health anxiety. Here follows a list of viable 
questions for future investigation: 
 Do the new DSM-5 diagnoses for severe health anxiety predict the effect of CBT or 
provide information about psychological processes that could be targeted in CBT? 
 What are the effects of G-ICBT, U-ICBT, and BIB-CBT for severe health anxiety in 
(particular sectors of) routine care? 
 What are the most cost-effective ways of implementing G-ICBT and FTF-CBT for 
severe health anxiety in (particular sectors of) rotuine care? 
 What are the relative effects of G-ICBT and FTF-CBT for severe health anxiety in 
the very long term? 
 Does the use of automated weekly reminders significantly increase the effect of U-
ICBT and BIB-CBT for severe health anxiety, and if so how is this effect optimised? 
 Would it be possible to predict the main outcome of CBT for health anxiety based on 
more sophisticated statistical models? 
 What is the ideal length of CBT for severe health anxiety? 
 What is the necessary training for a therapist in G-ICBT for severe health anxiety? 
 What can be done for partial responders and non-responders after CBT? 
 What is predictive of adverse events in CBT for severe health anxiety, and how can 
these events be avoided or minimised? 
 To what extent do the effects of minimal-contact CBT, and CBT for severe health 
anxiety in general, generalise to other cultural contexts and health care systems? 
4.10 CONCLUDING REMARKS 
Based on this thesis, there now exists a promising structured interview specifically designed 
for the assessment of DSM-5 SSD and IAD. U-ICBT and BIB-CBT demand little health care 
resources but nevertheless appear to be efficacious treatments for severe health anxiety, and 
thus deserve further use and evaluation. Importantly, it has also been shown that G-ICBT is at 
least as efficacious as FTF-CBT in the treatment of severe health anxiety. The availability of 
CBT for this patient group can thus be markedly improved through wider implementation of 
G-ICBT in routine care.  
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